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Background: Nutritional factors as modifiable cognitive protective/risk factors have 
been examined in recent years, published findings are inconsistent and/or insufficient. 
Few data are available for Asian population. 
Objective: To investigate aspects of the relationship between selected nutritional factors 
(albumin, hemoglobin, low body mass index, homocysteine, folate, and vitamin B-12), 
and cognitive performance, cognitive decline, and possible effect modification by 
Apolipoprotein E (APOE) genotype among Chinese older adults aged 55 and above. 
Methods: Population based study with both cross-sectional and longitudinal study 
designs. A group of Chinese older adults (N=2611) were assessed at baseline and were 
reassessed one to two years later. Cognitive performance was measured by Mini-Mental 
State Examination both at baseline and follow-up. Weight, height, serum albumin, 
hemoglobin, serum folate, serum vitamin B-12, plasma total homocysteine, and APOE 
genotype were measured at baseline. Data collected on confounding variables included 
cigarette smoking, alcohol consumption, cardiometabloic risk factors, activity of daily 
living, and depression. A comprehensive neuropsychological test battery was 
administered on a random subsample (N=841) at baseline. Study I investigated the 
relationships between body mass index, albumin, hemoglobin and cognitive performance. 
Study II investigated the effect of serum albumin on cognitive performance and cognitive 
decline and the effect modification by APOE genotype. Study III investigated the 
independent effects of folate, vitamin B-12, and homocysteine on specific cognitive 
functions. Study IV investigated the role of APOE ε4 as a genetic predisposing factor 
modulating the effect of vitamin B-12 on cognitive performance. 
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Results: Study I found that low hemoglobin in the bottom quintile (OR, 1.56; 95%CI, 
1.00-2.47) and low BMI-with-chronic comorbidity (OR, 1.73; 95%CI, 1.02-2.95) were 
independently associated with poor cognitive performance (MMSE ≤ 23).  Study II 
showed that decreasing levels of albumin were associated with an increased risk of 
cognitive impairment (P for trend=0.002), and with cognitive decline (P for trend=0.001). 
APOE- ε4 modified the association (P for interaction=0.049). Study III showed that 
homocysteine (log transformed) was inversely associated with performance on Block 
Design (β = -0.319, P=0.006) and Symbol Digit Modality Test written version (β= -
0.129, P=0.031). Folate (log transformed) was significantly associated with Rey Auditory 
Verbal Learning Test delayed recall (β= 0.139, P=0.010), verbal learning (β= 0.112, 
P=0.038), percentage of forgetting (β= -0.139, P=0.013) and Categorical Verbal Fluency 
(β = 0.104, P=0.042). Study IV found that low vitamin B-12 was associated with poorer 
performance on several cognitive measures in APOE ε4 allele carriers but not in non-
APOE ε4 carriers. The interaction between low vitamin B-12 and APOE ε4 was 
significant for MMSE (P=0.007), Digit Span backward (P=0.006), and RAVLT 
immediate recall (P=0.02). 
Conclusions: Poor nutritional status was associated with poor cognitive performance. 
Low albumin was independently associated with cognitive decline, and its association 
was more pronounced in carriers of the APOE-ε4 allele.  Folate and homocysteine was 
independently related with different cognitive domains. Vitamin B-12 was associated 
with cognitive performance in the presence of APOE ε4.  
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CHAPTER 1 INTRODUCTION 
With rapid worldwide population aging, the prevalence of cognitive impairment and 
dementia is expected to increase rapidly. Since there is no cure for dementia presently, it 
is extremely important to find modifiable risk and protective factors for cognitive 
impairment and decline, in order to prevent cognitive impairment, slow cognitive decline, 
and delay the onset of dementia. This thesis focused on aspects of the relationship 
between cognitive function, cognitive decline and selected nutritional factors in 
community-living Chinese older adults, namely albumin, hemoglobin, body mass index, 
homocysteine, folate, and vitamin B-12. The role of Apolipoprotein E as an effect 
modifier was also explored. Chapter 1 presented the general background and context of 
current study. More detailed literature review was covered in Chapter 2. 
 
1.1 Fast ageing population and its impact 
It is well known that the world’s population is aging very fast due to the low birth rate 
and prolonged life expectancy. As a result, the proportion of elderly people is expected to 
increase rapidly in the coming decades. Take Singapore as an example, in 2000, the 
proportion of persons aged 65 and older only accounted for 7.3% of the population. 
However, it is estimated that this will rise to 19% by 2030, making Singapore the country 
with the highest rate (5.3% annually) of population aging in the world. (1) 
 
Age is the most important single risk factor of dementia and the prevalence of dementia 
increases with advancing age. As a consequence of the ageing population, the prevalence 
and incidence of dementia is expected to increase very fast.  In 2006, the worldwide 
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 estimate of Alzheimer’s diseases prevalence shows that 26.6 million people were living 
with the disease. However, it is predicted that global prevalence of Alzheimer’s will 
quadruple by 2050 to more than 100 million, at which time 1 in 85 persons worldwide 
will be living with the disease.  More than 40 percent of those cases will be in the late 
stage Alzheimer’s requiring a high level of attention equivalent to nursing home care.(2) 
 
Given the high cost of treating and caring for dementia patients, we can be definite that 
dementia will be a devastating public health problem in the 21st century if we fail to find 
effective preventive strategies to maintain and promote cognitive health of the elderly 
population. On the other hand, even small increments in delaying in dementia onset and 
progression can significantly reduce the global burden of the disease.(2) Therefore, a 
better understanding of cognitive function and cognitive decline in the elderly population 
is clearly needed.   
 
1.2 Cognitive function and cognitive decline in elderly population 
From a cross-sectional view, the cognitive function of elderly population could be viewed 
as a continuum, which ranges from optimal or normal cognitive function at one end to 
dementia at the other end. In the past years, several terms have been used to describe an 
intermediate stage between the two ends. More recently, the construct of mild cognitive 
impairment (MCI) was proposed to designate an early, but abnormal, state of cognitive 
impairment. However, the distinction between normal ageing and MCI can be quite 
subtle and the specific transition between MCI and very early dementia is also fraught 
with uncertainties.(3) Thus, the conceptual scheme of a cognitive continuum is widely 
adopted in population-based studies. In those epidemiological studies, screening test 
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 scores (e.g. Mimi-Mental State Examination Test, MMSE) are widely used as a measure 
of global cognitive function while more sensitive neuropsychological tests are 
administered when specific cognitive domains are the research interest. 
 
From a longitudinal view, cognitive function declines with increasing age. This decline is 
universal and has been well documented although the rate of decline has not yet been 
established. Varied decline rate were reported from existed studies. For studies using 
MMSE, the mean annual decline ranged from 0.1 to 1.3 for those studies including 
patients with dementia at study entry and the mean annual decline for studies excluding 
patients with dementia ranged from 0.16 to 0.56 MMSE points.(4) Even though the 
accurate ‘normal’ rate of cognitive decline is still not clear; a much faster decline rate 
usually suggests pathological origins and represents the prodromal stage of dementia.  
 
1.3 Nutrition as potential modifiable cognitive risk/protective factor 
Since there is presently no cure for cognitive impairment and dementia, it is of great 
importance to identify modifiable risk and protective factors for potential early 
prevention and intervention.  
 
Research over the past decades has identified a number of established risk factors and 
protective factors for cognitive impairment and decline. Common known factors include 
age, education, Apolipoprotein E genotype, cardiovascular risk factors, mental activities, 
physical activities and social engagement. Unfortunately, most of these factors cannot be 
modified (age, education, APOE genotype) or are difficult to modify / change 
(cardiovascular risk factors, physical activities, mental activities and social activities); 
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 therefore, it is important to find modifiable cognitive risk and protective factors that are 
relatively easy to manipulate. Nutrition is a promising area that has attracted research 
interests in recent years. 
 
Previous researchers have explored the relationship between cognitive function and 
dietary intake (e.g. vegetable and fruits consumption, fish consumption), macronutrient 
(e.g. n-3 poly unsaturated fatty acid), micronutrient (e.g. vitamin-E, vitamin C, folate, 
vitamin B-12, homocysteine), and alcohol intake.(5, 6) Published results are suggestive 
and the prospects are promising. However, available evidence is still inconsistent and no 
definite conclusions can be drawn at present.   
 
Since nutritional status is modifiable through dietary or supplement intervention, the 
public health impact is huge when the association between a nutritional factor(s) and 
cognitive function is firmly established. Large population-based studies on this topic are 
necessary although the final definitive conclusion may have to come from well designed 
randomized controlled trials directed by the results of observational population studies.  
 
1.4. Objectives of the current study 
Using data from a community based study sample of older Asian adults (aged 55 and 
above) from the Singapore Longitudinal Ageing Studies (SLAS), the thesis focuses on 
aspects of the relationship between cognition and selected nutritional factors: albumin, 
hemoglobin, low body mass index, folate, homocysteine and vitamin B-12 and potential 
effect modification by APOE genotype. Among these factors, albumin, hemoglobin and 
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 body mass index are conventionally considered as clinical markers of general nutritional 
status while the two B-vitamins are closely associated with homocysteine in one-carbon 
metabolism. Accordingly, several related but independent studies were conducted. For 
ease of reference, each study is referred as Study I, Study II, Study III and Study IV 
respectively throughout the thesis.  
 
The objectives are:  
Study I: To examine the relationships between serum albumin, hemoglobin and body 
mass index with cognitive performance (measured by MMSE) among community-living 
older adults. Study II: To examine the relationships between serum albumin and global 
cognitive decline (measured by MMSE) and its effect modification by APOE-ε4 among 
community-living older adults. Study III: To examine the independent associations 
between homocysteine, folate, vitamin B-12 and cognitive performance (measured by 
MMSE and neuropsychological tests) in community-dwelling elderly Chinese with 
generally well cognitive (Mini-Mental State Examination score equal or above 24) and 
physical functioning (fully independent on Activities of Daily Living). Study IV: To 
examine the role of APOE ε4 as a genetic predisposing factor modulating the effect of 
vitamin B-12 on cognitive function (measured by MMSE and neuropsychological tests) 
in “cognitively normal” community-dwelling elderly Chinese (no cognitive impairment 
and cognitive decline).  
 
Hopefully, this series of studies would contribute to the understanding of the roles of 
nutritional factors on cognitive functioning in older adults. It could provide the evidence 
  5
                                                                                                                                           
 
 
 and rationale for the design of future clinical trials and the establishment of a prevention 
and intervention framework for cognitive impairment. Furthermore, the introduction of 
APOE genotype in this study could expand our knowledge of gene-environmental 
interaction in the development of cognitive impairment and cognitive decline. Lastly but 
importantly, these studies systematically investigated the relationship between nutrition 
and cognition in an Asian population on which little has been known so far, since most 
published studies have been conducted on Western populations. 
 
Nevertheless, it should be pointed out that there were limitations that were inherent in the 
designs of these studies. Firstly, the baseline measurements only covered limited aspects 
of geriatric nutrition and thus these studies do not provide a complete picture of the 
relationship between nutrition and cognition. Secondly, given the time constraints of a 
PhD thesis, the interval between baseline and follow-up MMSE assessment was short 
(median=1.5 year) and might not be long enough to reveal significant associations. 
Thirdly, the detailed neuropsychological tests were only administered at baseline (re-
assessment is conducted at about 30 months after baseline, the follow-up is ongoing and 
only about 287 participants have been re-assessed so far) and thus studies of the temporal 
relationship involving detailed neuropsychological functioning data, though desirable are 
not feasible. Future data from the SLAS 2nd wave of follow-up and neuropsychological 
assessment follow-up should provide more evidence in the future. 
 
A few other studies were conducted during the author’s PhD candidature (e.g. folate and 
depression, tea consumption and cognitive function, and others) but were excluded after 
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 careful consideration: depression is not the main interest of this thesis and tea as a 
traditional beverage may not be regarded as a marker of nutritional status; hence, 
manuscripts of these studies were not included in order to preserve integrity and 










































CHAPTER 2 LITERATURE REVIEW 
The literature review focuses on clinical and epidemiological studies that are related to 
this thesis.  
 
2.1 Nutritional status and cognitive function  
In the past, both overall dietary intake and conventional clinical markers of nutritional 
status (albumin, hemoglobin and body mass index) have been employed as indicators of 
nutritional status by researchers who investigated the relationship between nutrition and 
cognitive function in elderly people.  
 
2.1.1 Diet and cognitive function 
Huijbregts et al (7) hypothesized that a healthy and well-balanced diet, rather than the 
intake of isolated nutrients or foods, may lead to good cognitive function. They 
investigated the relationship between dietary patterns and cognitive function (measured 
by MMSE) in five different cohorts of elderly men using a healthy diet indicator (HDI) 
developed on the basis of the World Health Organization (WHO) dietary 
recommendations for the prevention of chronic diseases. Although not entirely consistent 
in all of the five studied cohorts, their findings suggest that a healthy diet may be 
associated with better cognitive function in elderly men.  Correa Leite et al verified this 
finding (8) in a bigger study population that included both men and women. After 
adjustment for age, gender, education, total energy intake, cigarette smoking, alcohol 
consumption and physical activity, it was shown that a better healthy diet score was 
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 associated with a lower prevalence of cognitive deficit. The cumulative odds ratio for any 
level of cognitive deficit per unit of the healthy diet indicator was 0.85 (95% CI 0.77 – 
0.93); which denoted that one unit increase on the healthy diet indicator was associated 
with 15% decrease on the probability of any level of cognitive impairment. Furthermore, 
in cumulative-odds model that excluded the participants who were subsequently 
diagnosed as being demented and those with severely/marked degree of dependency, the 
results remained unchanged. However, because of the nature of cross-sectional study 
design, no cause-effect relationship between dietary intake and cognitive function could 
be drawn from those studies. It is possible that cognitive impairment influences dietary 
habits rather than dietary intake influences cognitive function. On the other hand, dietary 
intake itself may not be an accurate indicator of nutritional status of the elderly people 
because many other important factors (e.g. defective dentition, gastrointestinal 
maldigestion and malabsorption, food-drug interactions) have not been taken into 
account. For that reason, biochemical or anthropometric markers have been utilized to 
represent nutritional status in other studies. As such, literatures on albumin, hemoglobin 
and body mass index are reviewed in the following sections. 
 
2.1.2 Albumin and cognitive function 
Albumin is a small, highly-soluble protein (M, 69,000) that is present in human plasma at 
high concentrations around 40 g/L, and is rapidly turned over. Its functions in the 
regulation of osmotic pressure and transport of many substances, including fatty acids 
and drugs, are well known. In recent years, it has also been shown that albumin plays 
important defensive roles in inflammation and infection (9), fibrinolysis, hemostasis and 
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 platelet aggregation (10), and oxidative damage (11). As such, albumin has been 
proposed to be a marker of susceptibility to the inflammatory response and increased 
vascular permeability that underlie various chronic diseases (12).  
 
Longitudinal cohort studies of large populations have demonstrated that reduced levels of 
serum albumin across the entire ‘normal’ range was inversely associated with the risk of 
coronary heart disease, stroke and all cause-mortality, as well as diabetes mellitus and 
other cardiovascular risk factors (12-18). However, few studies have examined the 
association between albumin and cognitive function.  
 
In a small case-control study (15 cases vs. 15 controls), Maes et al (19) found that serum 
albumin was significantly lower in Alzheimer’s disease patients (38.19 mg/L)  compared 
with age-matched, healthy controls (42.46 mg/L); the authors discussed the results from 
the perspective of the activation of inflammatory response system (IRS). Nevertheless, 
from a nutritional point of view, the observed difference may just reflect poor nutritional 
status of dementia patients after the onset of the disease. Evidences from non-demented 
elderly population are necessary before any firm conclusion could be drawn.  
 
The Gruppo Italiano di Farmacovigilanza nell’Anziano (G.I.F.A.) study studied the 
relationship between albumin and cognition in hospital patients. Among 3628 
hospitalized elderly people (patients admitted for general medical care at 35 hospitals), it 
was found that increasing serum albumin concentration was associated with decreasing 
cognitive impairment (20). Similar results were found in a more homogenous sample 
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 (only heart failure patients) in the GIFA study; among those patients, low albumin 
(albumin < 3.5 g/dL)  was  independently associated with cognitive impairment (OR 
1.78, 95% CI: 1.35–2.34) after adjustment for a wide range of potential confounders (21).  
Even though consistent results were found from the two large sample size studies, it 
should be pointed out that those findings may not be generalized for the elderly 
population since the hospital patients may differ from community living elderly on many 
important characteristics. 
 
Results from the community based studies were insufficient and inconsistent at present.  
In a study of 137 elderly (aged 66-90 years) community residents, La Rue et al (22) 
found that serum albumin was significantly correlated with logical memory scores 
(r=0.18, P<0.05). Given many other significant associations between nutritional factors 
(blood concentration, dietary intake and supplement) and cognition that were found in the 
same study, a general relation between nutritional status and cognition was suggested. 
The Longitudinal Aging Study Amsterdam (LASA) examined the relationship between 
albumin and cognitive decline in 1284 participants aged 62 to 85 years who have been 
followed up for 3 years from the baseline (23). It was shown that the lowest tertile of 
albumin (29.4-42.9 g/L) was borderline associated with MMSE decline (OR 1.54, 95% 
CI: 1.00 to 2.37). However, the OR became non-significant (OR 1.53, 95% CI: 0.98 to 
2.38) when those participants with a baseline MMSE score less than 21 were excluded, 
which suggested that the borderline significant association between low albumin and 
cognitive decline was possibly due to the inclusion of dementia cases at the baseline.  
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 Although a few studies on the relationship between albumin and cognition have been 
published, it remains a topic of debate. Firstly, it is not clear whether low albumin is 
related to higher risk of cognitive impairment. Secondly, it is not clear whether low 
albumin is related to a faster rate of cognitive decline. Thirdly, it is not clear whether 
albumin is related to cognition in dementia free elderly. In view of these, a community-
based longitudinal study with large sample size is needed. 
 
2.1.3 Hemoglobin and cognitive function 
Hemoglobin levels decline with age (24) and anemia is widely considered to be an 
important health problem among older individuals. While a growing body of evidence 
has linked adverse events with even ‘‘mild’’ anemia or low-normal hemoglobin in the 
elderly (25), limited epidemiologic studies that investigated the link between anemia and 
cognitive function and dementia risk have produced inconsistent results.  
 
In a case-control study that involved 192 matched female pairs and 63 matched male 
pairs, Beard found that the OR for AD among those with a low hemoglobin value (< 13 
g/dL for men and < 12 g/dL for women) at any time within the 2-year window of interest 
(onset year and preceding year for cases and corresponding years for controls) was 1.88 
fold (95% CI, 1.17-3.03), which suggested that anemia may be a risk factor for the 
development of AD.(26) However, the retrospective cohort study conducted by the same 
authors failed to reveal overall increase in risk of AD for anemia (Standardized Incidence 
Ratio, 0.98; 95% CI, 0.67-1.37) and consequently a causal relationship was not 
supported. Although the authors claimed that it was difficult to postulate any biologically 
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 plausible mechanism between anemia and Alzheimer’s disease, they believed that more 
research should be conducted to confirm or reject this interesting preliminary finding. 
 
A later prospective community-based longitudinal study confirmed the association 
between anemia and dementia. In the Kungsholmen Project (27), 1435 non demented 
participants aged 75–95 years were followed for 3 years and incident dementia cases 
were identified according to DSM-III-R criteria during the follow-up. It was found that 
anemia participants had higher hazard ratios of developing dementia (HR 1.5, 95% CI: 
1.0–2.3) after adjust for age, gender and education. Furthermore, for those participants 
with good cognition at base-line (MMSE >= 26), the association (WHO criteria for 
anemia, HR= 2.0, 95% CI: 1.0–3.8 ) was still significant after further control for chronic 
diseases, inflammatory markers (high white blood cells, high blood sedimentation rate), 
and other indicators of nutritional status (low albumin, low body mass index). With 
regard to the lack of association among participants cognitively impaired at base-line, the 
authors argued that it might be due to an underestimation of dementia cases among 
deceased participants (person with lower cognition and lower hemoglobin concentration, 
that had a higher risk of dying during the follow-up, had a lower probability of being 
classified as demented in the study). Since the hazard ratios of incident dementia was 
higher when lower hemoglobin cut offs were used to define anemia, a dose–response 
relationship between hemoglobin levels and risk of dementia was proposed and the 
authors postulated that the biological mechanism underlying this association could be a 
chronic brain hypo-oxygenation due to anemia. 
 
  13
                                                                                                                                           
 
 
 Several cross-sectional studies have examined the relationship between anemia and 
cognitive performance in the elderly. In the GIFA study, it was found that low 
hemoglobin levels and anemia were independently associated with cognitive impairment 
(defined as the Abbreviated Mental Test score <7) in older persons admitted to acute care 
units.(28) Significant association between anemia (defined as hematocrit < 38 for male 
and hematocrit < 36 for female) and cognitive impairment (defined as MMSE < 24) was 
also observed in a Greek study which involved 536 elderly aged 65 years and above from 
three settings ( those who were: a. living in the Elderly People's Home, N=48; b. visiting 
the Open Centre for Elderly People during 20 workday, N=75; c. visiting one health 
centre for routine medical care,  randomly selected, N=413).(29) Interestingly, results 
from the Caerphillly cohort of older men revealed a U-shaped relationship between 
hematocrit and cognitive function; which suggested the influence of both anemia and 
polycythaemia on cognitive function. (30) However, it is noticed that two of those studies 
used non-community based sample (28, 29) and one study (30) only involved men. At the 
same time, different laboratory measurement (hemoglobin or hematocrit) makes direct 
comparison between the studies difficult and cross-sectional study designs limits the 
inference of any causal association. 
 
With a prospective cohort study design, Denny et al examined the relationship between 
anemia (World Health Organization criteria) and cognition (measured by the Short 
Portable Mental Status Questionnaire, SPMSQ) among 1744 community dwelling 
elderly. They found that anemia was strongly associated with cognitive function (P 
<0.0001), and predicted decreases in both over a 4-year period.(31) Given the nature of 
  14
                                                                                                                                           
 
 
 longitudinal study design, a cause-effect relationship between low hemoglobin and 
cognitive function is indicated though it can only be firmly established after replication 
by more population based studies.  
 
2.1.4 Body mass index and cognitive function 
Body mass index is calculated as weight in kilograms divided by the square of height in 
meters (kg/m2) and is commonly used as a measure of both obesity and nutritional status. 
The relationships between body mass index, dementia risk and cognitive function is 
complex due to age-related changes in body composition. The picture might be different 
when the association is examined at different life stages; and it can be further 
complicated by body weight loss of early dementia patients in older adults. Hence, a life-
course approach is recommended to be adopted and caution need to be exercised when 
we interpret the results from a particular study. 
 
In mid-life time, BMI is generally considered as an indicator of body fat or adiposity, and 
emerging evidence support that increased BMI (obesity and overweight), especially in 
middle-age, is an independent risk factor for dementia and poor cognitive performance 
(32-34); this association might be due to vascular disorders or bioactive hormonal 
compounds that are secreted by adipose tissue.(32) The study conducted by Whitmer et 
al. had  the largest sample size (N= 10,136) and longest follow-up period (an average of 
36 years) among all the studies published as of today (35); in this study, it was found that 
compared to those with a normal BMI (18.5-24.9), those obese (BMI > or = 30) at 
midlife had a 3.10 fold increase in risk of AD (HR=3.10, 95% CI 2.19-4.38), and a five 
fold increase in risk of VaD (HR=5.01, 95% CI 2.98-8.43) while those overweight (BMI 
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 > or = 25 and <30) had a two fold increase in risk of AD and VaD (HR=2.09, 95% CI 
1.69-2.60 for AD and HR=1.95, 95% CI 1.29-2.96 for VaD). 
 
In older adults, significant relationships between low BMI and BMI decline with 
dementia risk and/or cognitive decline have been reported though the results did not 
totally agree with each other (36-39). These findings are interpreted to mean that the loss 
of BMI precedes dementia may reflect pathologic processes that contribute to the 
subsequent development of dementia rather than representing a true risk factor. We 
noticed that the follow-up period (32 years) of the Honolulu-Asia Aging Study (HAAS) 
(38) was comparable to the previously described large study conducted by Whitmer et al. 
(35). Interestingly, no effect of baseline BMI on dementia risk was observed in this study, 
and only during the last 6 years of follow-up, the adjusted mean weight loss was greater 
(-0.58 kg/year) for those with incident dementia compared with those not developing 
dementia (-0.22 kg/year). Although this study was conducted only in men and that could 
be a major limitation, it is noticed that levels of obesity were low in this cohort of 
Japanese American and this may contribute to the negative findings regarding baseline 
BMI.  
 
As for the association between BMI and cognitive performance, controversies exist even 
though numerous studies have been published.(32, 34, 40) As mentioned earlier, BMI 
changes during the life-course, especially at late stage, and the interpretation of BMI at 
different life stages might not exactly be the same, hence  direct comparisons of previous 
studies is difficult because that the influence of BMI on cognitive performance might 
change direction at certain life stage: the postulated inverse association between high 
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 BMI and cognitive function may disappear and increased BMI might appear to exert 
protective effect on cognition in elderly people. For example, the Advanced Cognitive 
Training for Independent and Vital Elderly (ACTIVE) trial (40) studied 2,684 
participants aged 65 to 94 and found that overweight participants had better cognitive 
performance in terms of reasoning and visuospatial speed of processing than normal-
weight participants.  
 
Since most of pervious studies are cross-sectional, select study population with different 
age range, have small sample sizes, and use different methods to measure cognitive 
function, the findings are expected to be inconsistent. In addition, we noticed that most 
previous studies have focused on obesity, while the relationship between low BMI as a 
measure of malnutrition and cognitive function was mostly neglected. Given the fact that 
large numbers of community-living elderly are known to be at risk of malnutrition, due to 
the high prevalence of chronic diseases, multiple drugs use, reduced mobility, and age-
related physiological and social changes (41), establishing the relationship between 
cognitive and nutritional status using nutritional markers such as BMI thus has practical 
significance. Body mass index, albumin, and hemoglobin could be examined together to 
reveal the possible independent effects. 
 
2.2 Homocysteine, folate, vitamin B-12 and cognitive function 
Recent research has investigated the link between homocysteine, folate, vitamin B-12 and 
the risk of dementia and cognitive impairment in older adults. The thiol-containing amino 
acid homocysteine links the methionine cycle with the folate cycle and is a sensitive 
marker for folate and vitamin B-12 deficiency (42, 43). In the methionine cycle, folate 
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 and vitamin B-12 are important cofactors for the remethylation of homocysteine to 
methionine.  
 
Hitherto, studies of the association of elevated concentrations of homocysteine, decreased 
folate and vitamin B-12 with cognitive function of elderly have yielded inconsistent 
findings.  Previous studies are discussed in the following sections according to the study 
designs. 
 
2.2.1 Case-control studies 
The majority of case control studies found significant association between elevated 
homocysteine and dementia risk (44-47), some researchers also revealed significant odds 
ratio of dementia for low blood concentration of folate (44, 47), or vitamin B-12 (44). 
Only Miller et al. (48) found a non-significant odds ratio of dementia for elevated 
homocysteine. It should be noticed that in Miller’s study, there were smaller portion of 
cases with vascular diseases compared with controls (11 out of 43 vs. 15 out of 37), and 
hence it is possible that the association between tHcy and AD was attenuated by the 
confounding of vascular diseases. Small sample size could be another possible reason for 
negative results. However, even significant associations between elevated homocysteine 
and decreased B vitamins and dementia are observed, we still cannot draw any causal 
conclusion because those concentration changes may occur after the onset of dementia.  
 
2.2.2 Cross-sectional studies 
In studies of non-demented healthy elderly populations, a number of investigators have 
reported an association of elevated homocysteine or decreased B vitamins with lowered 
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 cognitive performance (22, 49-62). Limited data from a few studies also suggest that 
homocysteine and folate might be associated differentially with specific cognitive 
domains (49, 56, 61).  Previous findings are somewhat inconsistent although more 
positive evidences exist.  
 
Differences in study population and study design could contribute to the inconsistency of 
published results.  For example, age may affect the associations between homocysteine, 
B-vitamins and cognitive function. Among the two Aberdeen Birth Cohorts, Duthie et al. 
found that most of the significant correlations between homocysteine, B vitamins and 
cognitive performance in 1921 Birth Cohort did not exist in the 1936 Birth Cohort (54).  
Childhood intelligence quotient was available in this interesting study and was adjusted 
in statistical analysis. The results suggest that the cross-sectional associations between 
homocysteine, B vitamins and cognitive performance are more pronounced with 
increasing age.  This was confirmed by the Framingham Offspring Study (60) later on; 
the study showed significant inverse associations between tHcy and cognitive 
performance in older (aged 60 or more years), but not in younger and middle-aged (aged 
less than 60 years), adult.   
 
The selection of cognitive measurements also could affect the results. Given equal 
sample size, more sensitive outcome measures surely have larger chance to reveal 
statistically significant associations.  Ideally, a comprehensive neuropsychological test 
battery that covers all the main cognitive domains should be administered to reveal 
possible differential effects. Since various screening tools (e.g. MMSE) and 
neuropsychological tests (e.g. Block Design) were used in previous studies, and the test 
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 battery (some studies only used screening test) differed from study to study,  some of the 
investigators might only observed parts of the whole picture and discrepancy to certain 
extents were expected.  
 
Although quite a number of studies have been published, we noticed that many of them 
have limitations. Some studies have limited sample size (22, 49, 52, 54, 58) or measured 
only a limited range of cognitive domains (51, 55, 62); some studies did not measure B 
vitamins and homocysteine simultaneously (22, 50, 52, 53, 59), and thus cannot examine 
the differential contributions of each of these closely associated micronutrients.  
 
In a tri-ethnic population, Wright reported that an association between homocysteine and 
MMSE score was observed only in White and Hispanic participants but not in Blacks 
(57). This suggests that ethnicity may also have a modulating effect, either in itself, or as 
a surrogate of ethnicity-related factors. To the best of our knowledge, no data on Asian 
elderly population has been reported. 
 
2.2.3 Cohort studies 
Longitudinal studies have reported positive findings linking elevated concentrations of 
homocysteine or lowered B vitamins with cognitive decline and dementia (63-68), as 
well as negative findings (69-72).  
 
The differences on some important characteristics between study populations may 
contribute to these inconsistent research data. For example, in the study population of 
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 Crystal et al. (69), only 22 participants had low vitamin B-12 concentration at base line 
while in Wang’s study (63), 101 out of 370 participants had low blood folate or vitamin 
B-12. The lack of elderly people with decreased blood concentration of B-vitamins in 
Crystal’s study may causes low statistical power and subsequently leads to negative 
result. This also could explain the negative findings regarding plasma homocysteine in 
some studies. It is noticed that in Kalmijn’s study population, the mean value of tHcy was 
15.6μmol/L (70) and in Luchsinger’s study sample (71), 64% of the participants had a 
homocysteine concentration >14 μmol/L; the number of participants with optimal plasma 
homocysteine concentration may not be sufficient to reveal statistically significant 
association. In other words, to study the relationship between dementia risk or cognitive 
decline and blood concentration of certain biochemical constituent, enough numbers of 
participants with low/high and normal/optimal concentrations are required. 
 
As for baseline cognitive status, Wang et al (63) found that among those with good 
cognitive function (defined as MMSE>26) at baseline, the RR of AD for low folate or 
vitamin B-12 is much higher (RR=3.1 for the MMSE>26 study population vs. RR=2.1 
for the whole study population), which suggest that baseline cognitive functioning level 
also could affect the results.  
 
The difference regarding the length between baseline and the last follow-up assessment is 
another crucial factor. In Seshadri’s study, it was found that elevated homocysteine at 
baseline was related to decline of MMSE score only after a follow-up period of at least 
four years (64). The association between homocysteine and dementia risk became 
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 increasingly clearer with longer follow-up length. The short time interval between 
baseline and follow-up assessment may explain the negative finding from the study 
conducted by Kalmijn et al.(70); in that study, 2.7 years follow-up may not be long 
enough to reveal the association even if it really exist .  
 
2.2.4 Clinical trials 
Although natural observation data suggested that homocysteine and B-vitamins may 
affect cognitive performance, early studies (73-81) did not support the cognitive benefit 
of B vitamin supplement. However, the maximum intervention period of previous trials 
was only 12 weeks (76) and may not be long enough to show any improvement. 
Additionally, most of these clinical trials were limited in sample size (small sample sized 
may lead to low power) and outcome measurement (screening tests like MMSE may not 
be sensitive enough) and thus were less likely to reveal positive findings. 
 
More recently, two RCTs with large sample size and long intervention period reported 
contradicting results. In the New Zealand study, after two years intervention, although 
plasma homocysteine concentration was significantly lower (4.36 μmol/L, 95% CI 3.81-
4.91, P<0.001) in the B-vitamins group than in the placebo group, no significant 
differences on cognitive performance were observed (82). On the contrary, the 
Netherlands study found that 3-year folic acid supplementation significantly improved 
the performance on memory (difference in Z scores 0.132, 95% CI 0.032 to 0.233), 
information processing speed (0.087, 0.016 to 0.158) and sensorimotor speed (0.064, -
0.001 to 0.129) as compared with the placebo group (83). Interestingly, for the most 
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 clinically relevant test, the delayed recall of word learning test, folic acid 
supplementation improved the performance by 0.47 words (95% CI 0.14–0.79, p=0.005), 
which was similar to a performance of an individual 6.9 years younger (95% CI 2.1–
11.8). Both studies purposely selected participants with high concentration of blood 
homocysteine as trial participants; however, we noticed that the Netherlands study (83) 
had larger sample size (N=818 vs. N=276), longer intervention period (3 years vs. 2 
years), and younger trial participants (mean age: 60 vs. 73.5) as compared with the New 
Zealand study (82). These differences in study features could together contribute to the 
discrepant results. 
 
2.3 Nutrition and cognitive function: the role of Apolipoprotein E Genotype 
Apolipoprotein E (ApoE) is a polymorphic 299-amino acids protein which has critical 
functions in redistributing lipids among CNS cells, repairing injured neurons, maintaining 
synapto-dendritic connections, and scavenging toxins (84). The gene, located on 
chromosome 19, encodes three alleles: ε2, ε3, and ε4, which combine to form 6 different 
genotypes.  The three isoforms differ by only one or two amino acids at residues 112 and 
158:  E3 has Cys-112 and Arg-158, whereas E4 has arginine at both sites, and E2 has 
cysteines. The deceptively small differences between the isoforms cause significant 
differences in structure and ultimately function. ApoE4 could promote Aβ-induced 
neuronal injury and also may act independently of Aβ (85). As proposed by Mahley et 
al.(84), there are three potential detrimental roles for ApoE4: (1) enhanced Aβ 
production, (2) potentiation of Aβ 1–42-induced lysosomal leakage and apoptosis, and 
(3) enhanced neuron-specific proteolysis resulting in translocation of neurotoxic ApoE4 
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 fragments in the cytosol, where they are associated with cytoskeletal disruption and 
mitochondrial dysfunction.  
 
Currently, the APOE ε4 allele is well known as a major genetic risk factor for dementia 
(86), and it is widely held that the presence of this genetic disposition may render 
individuals more vulnerable to environmental risk or modulate the influence of protective 
factors. However, studies that investigated genetic factors modulating the effects of 
nutritional factors on cognitive function are scarce. One study reported an interaction of 
vitamin B-12 status and APOE genotype on words free-recall (87) and face recognition 
(88) in very old (75 years and older) persons. In a more recent study, Hu et al. found that 
among high-functioning older persons, the odds ratio of high serum beta-carotene level 
for cognitive decline was 0.11 (95% CI, 0.02–0.57) in APOE ε4 allele carriers and 0.89 
(95% CI, 0.54–1.47) among those who were APOE ε4 negative (89). The gene-















CHAPTER 3 METHODS 
3.1 Participants 
All the participants of this study were selected from the Singapore Longitudinal Ageing 
Study (SLAS) which is a prospective cohort observational study of ageing and health 
among community-dwelling elderly Singaporeans.   
 
The studies reported in this thesis comprise a series of related cross-sectional studies of 
cognitive impairment based on baseline data and longitudinal cohort studies of cognitive 
decline based on follow up data collected at 1 to 2 years after baseline assessment. 
 
During recruitment and baseline data collection between September 2003 and December 
2005, participants were identified by door-to-door census from the whole resident 
population in five contiguous districts in South East Region of Singapore. All older adult 
residents who were Singaporean citizens or permanent residents aged 55 and above were 
invited to participate in the study. Residents who were physically or mentally 
incapacitated to give informed consent or participate were excluded. A total of 2804 
residents participated in the study (estimated response rate 78%). All participants gave 
signed informed consent for the study, which was approved by the National University of 
Singapore Institutional Review Board. Participants completed an extensive series of face-
to-face interviews, assessments and tests at baseline which were performed by trained 
research nurses, in the language or dialect (English or Chinese) preferred by the 
participants. An exhaustive neurocognitive assessment was performed on a one-in-three 
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 random sample of the participants who had sufficient visual, language and motor abilities 
that are required to complete the tests.  First follow up assessments at 1 to 2 years after 
baseline assessment was performed for physical and cognitive function (MMSE).  
Neurocognitive follow-up (MMSE and neuropsychological tests) was conducted 2 to 3 
years after baseline. The flow of participants in this cohort was summarized in Figure 1. 
 

















1. Estimated response rate= 78 % 
2. Plasma total homocysteine, folate and vitamin B-12 were measured for 588 participants  
3. Ongoing, 287 participants were re-assessed as of December 2008  
 
2804 participants Recruited1 
193 were non-Chinese 
879 completed Neurocognitive assessment 
38 were non-Chinese 
841 were Chinese2 
2611 were Chinese  
1673 completed first follow-up  
45 died  
Older adults aged 55 and above in South-East Singapore 
893 lost to follow-up
Neurocognitive assessment follow-up3 
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Study I: Cross-sectional study of relationships between serum albumin, hemoglobin and 
body mass index with cognitive performance. 
  
The data of Study I was based on 2550 Chinese participants assessed at baseline after 
excluding a small number (N=193) of Malays and Indians, and 61 participants without 
hemoglobin or MMSE data. From March 2005 to January 2007, 1673 Chinese 
participants completed re-interview.  
 
Study II: Longitudinal cohort study of the relationships between serum albumin and 
global cognitive decline (measured by MMSE) and its effect modification by APOE-ε4.  
 
The study population of Study II was 1654 Chinese participants with complete baseline 
and follow-up data after eliminating 19 participants with missing data on APOE genotype 
(N=10) and albumin (N=9). Non-participants from loss to follow-up were more likely to 
be men (P=0.015) and had lower MMSE scores at baseline (P=0.001), but did not differ 
by serum albumin level (P=0.44), age (P=0.20) or education level (P=0.084).   
 
Study III: Cross-sectional study of the independent associations of homocysteine, folate, 
and vitamin B-12 with cognitive performance in community-dwelling elderly Chinese 




                                                                                                                                           
 
 
 This study and Study IV involved baseline cognitive functioning data collected from 
MMSE and detailed neuropsychological tests performed on a one-in-three random 
sample of the participants who had sufficient visual, language and motor abilities that are 
required to complete the tests. Both Study III and Study IV were conducted on Chinese 
elderly participants only, because the numbers of Malay and Indian participants were 
small.  
 
For Study III, data were analyzed for 451 Chinese elderly participants aged 55 or above, 
who had MMSE scores ≥ 24, were fully independent on Activity of Daily Living, and 
who completed cognitive assessment and homocysteine, folate and vitamin B-12 
measurements between September 2003 and June 2005, after omitting a small number of 
participants with missing or extreme outlier data for smoking (one participant), alcohol 
consumption (one participant), GDS (one participant), homocysteine (one participant), 
folate (two participants), vitamin B-12 (one participant), and creatinine (one participant). 
Because not all participants completed the whole test battery and some tests (Trail 
Making Test, Block Design) were subsequently additions to the test battery, the results 
for different neuropsychological measures were based on varying numbers of participants 
(ranging from 72 to 451).  
 
Study IV: Cross-sectional study of the role of APOE ε4 as a genetic predisposing factor 
modulating the effect of B-12 on cognitive function in community-dwelling elderly 
Chinese with “normal” cognitive functioning.  
 
  28
                                                                                                                                           
 
 
 In Study IV, data were analyzed for 411 “cognitively normal” Chinese participants who 
were examined between September 2003 and December 2005 and had available data of 
vitamin B-12, APOE genotype and cognitive performance.  
 
The following participants were considered as incipient dementia cases and were 
excluded from analysis: 1) Mini Mental State Examination total score < 24 (N=66) at 
baseline; 2) The Informant Questionnaire on Cognitive Decline (IQCODE) (90) score > 
3.37 (N=12); 3) MMSE drop >= 1 point/yr from baseline to first follow-up (N=54); 4) 
MMSE drop >=1 point/yr from baseline to Neuropsychological assessment follow-up 
(N=34).   
 
In total, out of 562 participants who had complete data on vitamin B-12, APOE genotype 
and neuropsychological test performance, 151 (26.8%) participants were excluded. Data 
analysis were done for those 411 ‘cognitive normal’ or ‘non-demented” Chinese older 
adults who were aged 55 y and above at baseline.  
 
3.2 Questionnaire interview and clinical measurements 
3.2.1 Demographic data and substances use 
Socio-demographic data included age, gender and education (Nil, Primary, Secondary, 
Pre-U or Poly, and University). For the participants of Study III and Study IV, data on 
years of schooling was also collected.  
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 Information on tobacco consumption was used to categorize participants into current 
smokers, past smokers, or non-smokers. Information on alcohol consumption was 
collected by asking the participants “How much alcohol drinks do you regularly 
consume?”; the participants were classified as ‘never or rarely’, ‘less than 1 drink a 
week’, ‘more than 1 drink a week but less than 1 drink a day’, or ‘1 or more drinks a day’ 
accordingly. One drink was defined as a ‘can’ of beer, a glass of wine or a shot of liquor. 
 
3.2.2 Medical conditions and medication 
Participants were asked to report whether in the 12 months prior to the interview they 
were diagnosed and treated by a doctor for any one or more of the following medical 
conditions: hypertension, high cholesterol/hyperlipidemia, diabetes, stroke, heart attack, 
irregular heart beat (atrial fibrillation), heart failure, cataract/major eye problems, kidney 
failure, asthma, Chronic obstructive lung disease, arthritis, hip fracture, and other 
conditions specified by them.  Information on medication that the participants used in the 
past 12 months were also collected (name of medication, for what medical problem). 
 
In Study I and Study II, the presence of hypertension was defined by a self-report of high 
blood pressure, and/or treatment with anti-hypertensive drugs and/or sitting systolic 
blood pressure >140 mm Hg and/or sitting diastolic blood pressure  >90 mm Hg.  The 
presence of diabetes was defined as self-report of diabetes and/or treatment with oral 
hypoglycemic agents or insulin, and/or fasting blood glucose >7.0 mmol/L. Dyslipidemia 
was defined as self reported lipid abnormality, and/or total cholesterol ≥6.5 mmol/L 
and/or LDL-Cholesterol ≥4.1 mmol/L and/or TG ≥2.3 mmol/L and/or HDL-Cholesterol 
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 <1.0 mmol/L and/or total cholesterol: HDL-Cholesterol ratio >4.5.  In Study III and 
Study IV, self reported hypertension, diabetes, and cardiovascular diseases were used as 
covariates in the data analysis. 
 
3.2.3 Physical functional status 
Physical functional status was assessed by the participant’s dependence in performing 
basic activities of daily living (BADL) using items from the Barthel’s scale (91), and 
instrumental activities of daily living (IADL) from the Lawton scale (92). Functional 
disability was defined as needing help in one or more BADL or IADL tasks, and 
participants were categorized as independent, IADL disability only, or BADL disability.  
 
3.2.4 Global cognitive status 
This was assessed by the Mini-Mental State Examination (MMSE) (93), which measures 
global cognitive functioning on domains that included memory, attention, language, 
praxis and visuo-spatial ability. The Chinese version of the MMSE was externally 
validated for use in the local population in Singapore (94). MMSE was coded according 
to previous conventions: items were coded as zero if the participants refused or were 
unable to complete. Summed scores of MMSE range from 0 to 30, higher values denoting 
better cognitive functioning. Poor cognitive performance was defined by MMSE total 
score of 23 or less. This has been shown to have high sensitivity (95.5%) and specificity 
(83.5%) for detecting cases of dementia in Singaporean older adults (94).  Cognitive 
decline was assessed by a decline of 2 or more points in the MMSE test scores between 
baseline and follow-up assessments.  
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 3.2.5 Other questionnaire data 
The presence of depression was determined by the short 15-item version of the Geriatric 
Depression Scale (95), which had been externally validated for use in local population 
(96). The use of the Geriatric Depression Scale (GDS) avoids the measurement artefact 
due to overlapping symptoms of the somatic illness and symptoms indicative of 
depression.  A single question on self-rated health status asked ‘In general, would you say 
your health is excellent, very good, good, fair, poor?’, and was used to categorize 
participants as having ‘poor and fair’ versus ‘good, very good and excellent’ health. 
Participants at nutritional risk were identified using the Nutritional Screening Initiative 
(NSI) scale (97). 
 
Participation in leisure time activities were measured by the frequency (0=never, 
1=sometimes, 3=often) with which the participants engaged in ‘fitness activities’ 
(‘walking’, ‘exercise routines’ and ‘active sports’), social activities’ (attending religious 
services, visiting cinemas, restaurants, and sports events; day or excursion trips; playing 
cards, games; participating in social group activities, such as karaoke, dancing; joining a 
senior citizen club activities); ‘productive activities’ (hobbies such as gardening, 
painting; preparing meals; shopping; community work; other employment or business). 
Each participant’s level of leisure time activities was measured by categorizing the 
summed scores in tertile groups. Each participant’s level of leisure time activities was 
measured by categorizing the summed scores in tertile groups. 
 
3.2.6 Clinical measurements 
  32
                                                                                                                                           
 
 
 Height and weight was measured with a portable Seca stadiometer (Model 708 1314004, 
Vogel & Hake Hamburg, Germany), with body mass index (BMI) calculated as kg/m2. 
Low body mass index (BMI) was defined as BMI below 18.5 kg/m2, according to recent 
WHO Expert Consultation and Recommendations of the Taskforce for Obesity 
Prevention and Control in Singapore (98).  Sitting Systolic and diastolic blood pressure 
were measured according to standard procedure.  
 
3.3 Laboratory measurements 
Venous blood samples after overnight fasting were drawn during 9:00 a.m. to 9:30 a.m. 
according to standard procedures. Blood samples were transported to Singapore National 
University Hospital Referral Laboratory (NRL) on ice within two hours and the plasma 
or serums were isolated for analysis.  
 
Serum level of albumin (g/L) was measured on the same day on Advia 2400 auto-
analyzer using Bromcresol Green (BCG) dye binding method (Bayer HealthCare 
Diagnostics, with CV ranging from 1%-3%). The measurements of haemoglobin level 
(g/dL) and creatinine (µmol/L, Jaffe’s method) were performed on the same automated 
system (Advia 2400, Bayer HealthCare Diagnostics). Plasma total Homocysteine (tHcy) 
was measured by automated chemiluminescent enzyme immunoassay method 
(Diagnostic Products Corporation, Los Angeles, CA, USA); the CV ranged from 4.1% to 
10.4%. Folate and vitamin B-12 was measured in serum by radioassay with Elecsys 
Folate II reagent kit (CV ranged from 6.1% to 13.8%) and Elecsys Vitamin B-12 reagent 
kit (CV ranged from 3.2% to 7.6%), (Roche Diagnostic, Indianapolis, IN, USA). APOE 
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 genotyping was identified by PCR amplification followed by restriction endonuclease 
digestion of the PCR product (PCR-RFLP) (99). Other blood measurements included 
fasting glucose and lipids panel (total cholesterol, total triglyceride, LDL-Cholesterol, 
and HDL-Cholesterol).  
 
3.4 Neuropsychological assessment 
Trained research assistants administered a comprehensive neuropsychological test battery 
that assesses a wide range of cognitive domains including attention and working memory 
(Digit Span and Spatial Span), verbal learning and memory (Rey Auditory Verbal 
Learning Test), visual memory (Visual Reproduction), language and executive function 
(Categorical Verbal Fluency), executive function (Design Fluency), information 
processing speed (Symbol Digit Modality Test), visual conceptual ability, visual-motor 
tracking and mental flexibility (Trail Making test A and B), visual spatial and 
constructional ability (Block Design). The assessment was administered in English, 
Mandarin, or Chinese dialects according to the participant’s habitual language. The entire 
battery took one and a half hour to two hours to complete.  
 
Digit Span (100): In Digit Span Forward, the examiner reads strings of numbers in series 
with increasing length, and the examinee is asked to repeat the string in the exact order. 
In Digit Span Backwards, the examinee is asked to say the strings in reverse order.  
 
Spatial Span (101):  Using a computerized version of the test, Spatial Forward was 
performed by having the examinee touch the same square on the computer screen in the 
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 same order as they were flashed up (changing from blue to red). In the Spatial Backwards, 
the participant is asked to touch the squares in the reverse order.  
 
Rey Auditory Verbal Learning Test (102): The examiner reads a semantically unrelated 
word list (list A) to the examinee in a series of five trials. After each learning trial, the 
examinee is asked to repeat all the words he/she can remember. A second distracter word 
list (list B) is then presented. Thirty minutes later, the examinee is asked to recall all the 
words he/she can remember from list A again. 
 
Visual Reproduction (101): The examinee is allowed 10 seconds to observe each of five 
design cards (three cards with one design and two cards with two designs) and reproduce 
them from memory. Thirty minutes later, the examinee is asked to reproduce the designs 
again.  
 
Categorical Verbal Fluency: The examinee is asked to produce as many words as possible 
in one minute from three categories (Animal, Vegetable and Fruit) respectively.  
 
Design Fluency (103): The examinee is asked to connect dots to make different designs 
with four straight lines in 60 seconds. In condition I, there are only black dots presented. 
In condition II, there are black and empty dots and the participant is asked to only use the 




                                                                                                                                           
 
 
 Symbol Digit Modality Test (104): In the written version, the examinee is asked to write 
as many numbers as he/she could in the boxes below a series of symbols according the 
key provided at the top of the page within 90 seconds. In the oral version, the examiner 
records the numbers spoken by the participants.  
 
Trail Making Test A and B (105): In Part A, the examinee is timed to connect the numbers 
in sequence as fast as possible with a pencil. In Part B, the participants is asked to switch 
between number and letters.  
 
Block Design (100): The examinee is asked to replicate models or pictures of two-color 
designs with blocks. The designs progress in difficulty from simple two-block designs to 
more complex, nine-block designs.  
 
3.5 Statistical analysis 
3.5.1 Study I: Cross-sectional analysis of the relationships between serum albumin, 
hemoglobin and body mass index with cognitive performance.   
 
Data were analyzed for 2550 Chinese participants. Participants were categorized into 
quintile groups of albumin and hemoglobin concentrations, the latter according to their 
respective values separately for men and women.  
 
Group comparisons of categorical and continuous variables were performed using chi-
squared test or analysis of variance, as appropriate. Odds ratio (OR) of association and 
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 95% confidence intervals (95% C.I.) were estimated in multiple logistic regression 
analyses. Crude OR were estimated in base models (Model I), and adjusted OR’s in 
hierarchical models that controlled for gender, age and education, dyslipidaemia, 
hypertension, cardiovascular disease, stroke, diabetes, creatinine, smoking, alcohol, 
depression, self-rated health, physical functional status, and APOE ε4 status (Model II); 
and finally with hemoglobin, albumin and low BMI together (Model III). In these 
models, creatinine and GDS scores were entered as continuous variables. Interactions 
between the primary and other independent variables were evaluated and tested in the 
models.   
 
In further analyses which excluded participants with MMSE ≤23, general linear 
regression modelling technique was used to compare adjusted mean MMSE scores 
among the albumin and hemoglobin quintile groups and BMI categories, controlling for 
confounding variables. Statistical analyses were performed using SPSS statistical 
software version 14.0 (SPSS Inc, Chicago IL). All reported statistical tests were two-
sided. A P value of < 0.05 was accepted as statistically significant.  
 
3.5.2 Study II: Cross-sectional and longitudinal analysis of the relationships between 
serum albumin and global cognitive decline and its effect modification by APOE-ε4. 
 
The association of albumin (in approximate tertile categories using cut-offs of <42, 42-
44, >44 g/L) with cognitive impairment and cognitive decline was examined in cross-
sectional analyses and longitudinal analyses respectively. In univariate analyses, tertile 
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 groups of albumin were compared on prevalence of cognitive impairment or decline and 
baseline characteristics, using one-way analysis of variance test for continuous variables 
and Chi-squared trend tests for categorical variables. Multivariable analyses were 
performed using binomial logistic regression with covariate adjustment models that 
included age (years), gender, education (0-6 years or more), number of medical 
comorbidity (none, 1-2, ≥3), hypertension, diabetes, cardiac diseases, stroke, smoking, 
alcohol drinking, depression (GDS ≥5 or less), APOE-ε4, nutritional risk (Nutrition 
Screening Initiative NSI score <3, ≥3), BMI (kg/m2), anemia (<12 in women, <13 in 
men), glomerular filtration ate (GFR, ml/min, from Cockroft formula). In longitudinal 
analyses, baseline MMSE score was included in the model to control for floor effect. 
Trends in the OR of cognitive decline across increasing serum albumin categories were 
determined, modelling albumin categories as an ordinal variable.  The interaction 
between albumin and APOE-ε4 status were tested in the models. Odds ratios (ORs) of 
associations were computed yielding point estimates with 95% confidence intervals (95% 
CI). The level of statistical significance was set at P<0.05 with two-tailed distribution. 
All analyses were performed using SPSS statistical software version 15.0 (SPSS, Inc., 
Chicago, Illinois). 
 
3.5.3 Study III: Cross-sectional analysis of the Independent associations of 
homocysteine, folate, vitamin B-12 with cognitive performance in community-dwelling 
elderly Chinese with generally well cognitive and physical functioning. 
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 Data were analyzed for 451 Chinese elderly participants. Multiple linear regression was 
used to examine the relationships between neurocognitive performance and 
homocysteine, folate and B-12 levels, controlling for potential confounding variables, 
and to evaluate whether these relationship were altered by these other variables. Firstly, 
the relationship between cognitive test scores and homocysteine, folate or vitamin B-12 
was examined individually in base models (I) that controlled for age, gender and number 
of years of education. In higher order models (II), more covariates were added:  
covariates cardiovascular risk factors (including cigarette smoking, alcohol consumption, 
body mass index, and total cholesterol); chronic diseases including hypertension, 
diabetes, cardiovascular disease (any of heart attack, heart failure, atrial fibrillation, or 
stroke); renal function (measured by creatinine), and depression (measured by Geriatric 
Depression Scale). In the final Models III, homocysteine, folate, and vitamin B-12 were 
entered into the regression models simultaneously with all previous covariates. Because 
homocysteine, folate, vitamin B-12 and creatinine data were highly skewed to the right, 
they were natural logarithmic transformed before data analysis. To facilitate meaningful 
comparisons of results across different cognitive tests with varying metrics, standardized 
Beta coefficient estimates are presented. All data analysis was done by SPSS 13.0 (SPSS 
Inc. Chicago, Illinois, US). 
 
3.5.4 Study IV: Cross-sectional analysis of the role of APOE ε4 as a genetic 
predisposing factor modulating the effect of B-12 on cognitive function in community-
dwelling elderly Chinese with “normal” cognitive functioning. 
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 Data were analyzed for 411 “cognitively normal” participants who were examined 
between September 2003 and December 2005 and had available data of vitamin B-12, 
APOE genotype and cognitive performance. Because not all participants completed the 
whole test battery and some tests (Trail Making Test and Block Design) were 
subsequently added to the test battery, the results for different cognitive measures were 
based on varying numbers of participants (ranging from 74 to 411). 
 
The association between vitamin B-12 and cognitive performance was examined in the 
whole study sample, and separately for APOE ε4 carriers and non- APOE ε4 carriers, 
using multiple linear regressions to control simultaneously for potential confounding by 
other risk factors.  Covariates in the regression models included age, gender, number of 
years of education, cigarette smoking (non-smoker vs. ex- and current smoker), alcohol 
consumption (non-drinker vs. regular drinker), hypertension, diabetes, and cardiovascular 
diseases (any of heart attack, heart failure, atrial fibrillation, or stroke). Because vitamin 
B-12 data was highly skewed to the right, it was natural logarithmic transformed before 
analysis. The interaction term (product of log transformed vitamin B-12 and APOE ε4) 
was then examined in the whole sample with all the covariates as well as log transformed 
vitamin B-12 and APOE ε4 status in the model. These models assume a linear 
relationship between cognitive performance scores across the continuum of vitamin B-12 
values.  
 
In instances where non-linear effects are plausible, examining vitamin B-12 as a 
continuous variable may not reveal statistically significant linear interaction. We 
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 therefore dichotomized vitamin B-12 using plausible cut-offs to explore possible 
threshold effects, and further examined interaction effects. The cut-off we used (250/251 
pmol/L) was shown to be sensitive to vitamin B-12–cognitive effects in early studies (87, 88) 
Where significant interactions were found, we reported for clarity of presentation the 
results of the adjusted means for four groups formed by vitamin B-12 status (low and 
normal) and APOE ε4 status (ε4 and no- ε4). Data analysis was done by SPSS 16.0 (SPSS 
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CHAPTER 4 RESULTS 
4.1 Study I: Cross-sectional study of the relationships between serum albumin, 
hemoglobin and body mass index with cognitive performance. 
 
The mean age of the participants was 65.8 years (SD 7.6, range: 55-98); 51.8% had less 
than 6 years of schooling. Poor cognitive performance (MMSE ≤23) was present in 298 
participants (11.7%); low albumin (below lowest quintile value <40g/L) in 497 
participants (19.5%), low hemoglobin (below lowest quintile cutoff of 12.2g/dl in 
females, and 13.3g/dl in males) in 472 participants (18.5%); low BMI (<18.5kg/m2) was 
found in 155 participants (6.1%), and 137 (5.4%) had low BMI together with one or more 
chronic medical condition(s). 
 
In univariate analyses, albumin quintiles, hemoglobin quintiles and BMI status were all 
significantly associated with poor cognitive performance. Demographic, vascular and 
other risk factors and correlates of poor cognitive performance varied across quintile 
groups of the nutritional variables (Table 1). In multivariable logistic regression analyses 
that controlled for gender, age, education, as well as vascular risk factors and other 
correlates, and in the presence of other nutritional variables (Table 2), low albumin and 
hemoglobin quintiles were independently associated with poor cognitive performance, 
but low BMI was not (Wald statistic 2.053, 1 df, P=0.15).  However, there was a 
significant interaction between low BMI and chronic comorbidity (Table 2, Wald 
statistic, 4.097, 1 df, P=0.043).  
 Table 1  Prevalence of Risk factors for Cognitive Impairment by Quintiles of Hemoglobin and Albumin and Low BMI-with-chronic comorbidity 
 Albumin Quintiles    Hemoglobin Quintiles  Low BMI-and-Chronic comorbidity 
Risk factors 1 2 3 4 5 P  1 2 3 4 5 P  Yes No P 
 N=497 N=531 N=613 N=524 N=385 trend  N=472 N=511 N=514 N=488 N=565 trend  N=137 N=2413  
                  
Cognitive Impairment 21.9 11.5 10.9 6.5 7.0 <0.001  20.1 12.9 9.3  9.6 7.4 <0.001  22.6 11.1  <0.001 
Female gender 68.8 62.0 62.8 60.7 61.8 0.06  62.7 62.6 65.0 63.7 62.1 0.88  59.9 63.4 0.40 
Age,  < 65 34.6 50.3 54.0 51.3 58.4   34.7 46.4 54.3 53.9 56.8   37.2 50.3  
          65-75 42.1 37.5 35.2 40.6 32.2   40.7 38.9 36.4 37.7 35.2   44.5 37.3  
          ≥ 75 23.3 12.2 10.8 8.0 9.4 0.001  24.6 14.7 9.3 8.4 8.0 <0.001  18.2 12.4 0.008 
Education: < 6 years 64.8 54.6 49.8 41.4 48.3 0.001  61.0 56.0 50.4 46.9 45.7 <0.001  60.6 51.3 0.034 
APOE e4 15.3 18.6 13.9 17.7 16.1 0.20  15.5 17.2 16.0 16.0 16.6 0.95  21.2 16.0 0.11 
Hypertension  50.1 48.8 58.1 58.4 58.7 0.001  56.8 52.1 54.9 50.0 59.5 0.019  38.0 55.7 <0.001 
Hyperlipidemia 58.6 65.9 68.8 69.5 79.0 0.001  60.6 66.7 69.6 71.5 70.3 0.002  49.6 68.9 <0.001 
Diabetes mellitus  14.7 14.7 16.0 16.0 17.7 0.74  20.8 14.1 15.8 15.0 13.6 0.016  5.8 16.3 0.001 
Coronary heart disease 2.6 3.0 2.6 1.5 1.8 0.49  3.6 2.3 2.1 2.7 1.2 0.16  1.1 2.6 0.41 
Congestive heart failure  4.0 3.6 2.1 3.6 3.9 0.39  4.2 3.7 3.7 3.7 1.8 0.20  2.9 3.4 0.76 
Stroke  5.0 2.8 4.2 3.8 2.1 0.14  5.1 4.3 2.1 4.3 2.8 0.08  3.8 3.7 0.98 
Chronic comorbidity 92.0 94.0 95.4 92.2 95.8 0.027  93.2 93.5 93.0 94.1 95.2 0.57  99.2 93.5 0.002 
Alcohol use, daily ≥ 1 drinks 2.2 3.0 1.1 1.1 1.8 0.11  1.5 2.3 1.6 0.8 2.8 0.13  4.4 1.7 0.023 
Past or current smoker 19.7 17.5 15.7 14.1 13.8 0.07  16.9 16.0 15.4 15.6 17.2 0.91  24.8 15.1 0.005 
Self-reported health: fair or poor  35.0 31.3 33.6 27.5 32.7 0.09  37.1 32.7 29.8 32.6 28.7 0.043  34.3 31.9 0.55 
GDS score, mean±SD 2.1 ±2.9 2.2±3.0 1.6±2.3 1.6±2.5 1.9±2.8 <0.001  2.4±3.1 1.9±2.7 1.9±2.9 1.6±2.4 1.7±2.6 <0.001  2.5±3.3 1.8±2.7 0.008 
Physical function disability                  
    None 70.2 74.0 76.5 80.0 76.4   65.3 72.0 79.8 78.5 80.5   65.0 76.0  
    IADL disability only 20.5 20.0 17.6 15.8 18.7   25.6 20.0 16.5 17.6 13.6   21.9 18.3  
    ADL disability 9.3 6.0 5.9 4.2 4.9 0.012  9.1 8.0 3.7 3.9 5.8 <0.001  13.1 5.7 0.027 
Leisure time activity level                  
  < 8 39.2 33.5 29.7 30.5 32.2   39.6 32.9 31.7 29.9 31.0   43.1 32.3  
  8-11 34.2 32.8 35.7 34.7 39.5   32.0 36.0 35.4 37.3 35.0   32.1 35.4  
  ≥ 12 26.6 33.7 34.6 34.7 28.3 0.006  28.4 31.1 32.9 32.8 34.0 0.09  24.8 32.3 0.043 
Creatinine, mean±SD, µmol/L 82.3 ± 46.9 80.2 ± 20.4 80.6 ± 22.7 78.9±19.0 81.4±23.6 0.38  86.3± 38.4 81.0± 38.0 78.0±19.8 78.5± 18.2 79.9±19.6 <0.001  76.0± 19.9 80.9±28.6 0.046 
Albumin, mean±SD, g/L        40.8± 3.5 41.8± 3.0 42.6± 3.0 42.5± 3.1 43.2± 2.9 <0.001  41.0± 3.7 42.3 ±3.2 <0.001 
Hemoglobin, mean ± SD, g/dL 12.9±1.3 13.5±1.3 13.5±1.3 13.7±1.3 13.9±1.4 <0.001         12.9±1.3 13.5±1.4 <0.001 
                 
 
All values are given as number (percentage) unless otherwise indicated.  Hemoglobin quintiles were defined for women as: <12.2, 12.2 to 12.7, 12.8 to 13.2, 13.3 to 13.7, and ≥13.8 g/dL, respectively. In men, 
these were <13.3, 13.3 to 14.1, 14.2 to 14.7, 14.8to 15.3, and ≥15.4 g/dL. Albumin quintiles were defined:  < 40, 40-41, 42-43, 44-45, ≥ 46 g/L 
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Table 2 Multiple logistic regression model parameters: albumin, hemoglobin, low BMI, chronic 
comorbidity and low BMI * chronic comorbidity interaction.   
 
  Beta S.E. Wald df P 
Albumin   11.884 4 0.018 
   1 (< 40 g/L) 0.712 0.262 7.383 1 0.007 
   2 (40-41 g/L)  0.405 0.271 2.236 1 0.13 
   3  (42-43 g/L) 0.416 0.267 2.439 1 0.12 
   4  (44-45 g/L) 0.034 0.294 .013 1 0.91 
   5  (≥ 46 g/L) Reference     
      
Hemoglobin quintiles    4.560 4 0.33 
   1 (Men: <13.3g/dL; Women: <12.2 g/ dL)  0.474 0.234 4.107 1 0.043 
   2 (Men: 13.3-14.1 g/dL; Women 12.2-12.7g/dL) 0.299 0.237 1.588 1 0.21 
   3 (Men: 14.2-14.7g/dL; Women: 12.8-13.2 g/dL) 0.245 0.248 .977 1 0.32 
   4 (Men: 14.8-15.3g/dL; Women: 13.3-13.7g/dL) 0.395 0.250 2.502 1 0.11 
   5 (Men: ≥15.4g/dL; Women: ≥13.8g/dL) Reference     
      
Chronic co-morbidity 0.606 0.429 1.998 1 0.16 
      
Low BMI 0.384 0.268 2.053 1 0.15 
      
Low BMI * Chronic comorbidity 0.549 0.271 4.097 1 0.043 
   
 
Not shown in the table are covariates in model: gender, age, education, dyslipidaemia, hypertension, 
cardiovascular disease, stroke, diabetes, creatinine, smoking, alcohol, depression, self-rated health, physical 
functional status, leisure time activity level, APOE ε4 status.   
 
Albumin. The prevalence of poor cognitive performance increased from 7.0% to 21.9% 
with descending quintiles of albumin. In multivariable analyses (Model III, Table 3), the 
linear trend in OR’s across the albumin quintiles was statistically significant (P<0.001); 
the lowest albumin quintile was associated with a two-fold increased risk of poor 
cognitive performance (OR, 2.04; 95% CI, 1.22-3.41) independently of other risk and 
nutritional factors.  
 
Hemoglobin. The prevalence of poor cognitive performance increased from 7.4% to 
20.1% with descending quintiles of hemoglobin. In multivariable analysis (model III, 
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Table 3), the lowest hemoglobin quintile was associated with an increased risk of poor 
cognitive performance (OR, 1.56; 95% CI, 1.00-2.47) independently of albumin and 
other factors. However, there was no significant linear trend of relationship of poor 
cognitive performance across descending quintiles of hemoglobin.   
 
Low BMI and chronic comorbidity. We found that low BMI by itself was not 
significantly associated with poor cognitive performance, but in the presence of chronic 
comorbidity it was. We therefore estimated OR for low BMI-and-chronic comorbidity as 
a predictor variable. The prevalence of poor cognitive performance in participants with 
low BMI-and-chronic comorbidity was 22.6%, significantly more than in those without 
(11.1%). In multivariable analyses (model III, Table 3), low BMI-and-chronic 
comorbidity was associated with an increased risk of poor cognitive performance (OR, 
1.73; 95% CI, 1.02-2.95), independently of low albumin, low hemoglobin and other risk 
factors. 
 
We also repeated the analysis in a subset of participants (N=2252) after excluding those 
with poor cognitive performance (MMSE score ≤23). In these participants, increasing 
albumin quintiles showed a significant inverse linear relationship with MMSE scores (P 
for linear contrast=0.022) in general linear regression models which fully adjusted for 
confounding variables (Table 4). Neither hemoglobin quintiles nor low BMI-and-chronic 
comorbidity was significantly associated with MMSE scores in this analysis. 
  
 
   
Table 3 Odds Ratios (95% CI) of Association of Quintiles of Haemoglobin and Albumin and low BMI-
and-Chronic Illness with Cognitive Impairment 
 Model I Model II  Model III 
 OR 95% CI OR 95% CI  OR 95% CI 
Albumin        
   1st quintile 3.72 2.39, 5.81 2.20 1.32, 3.65  2.04 1.22, 3.41 
   2nd quintile 1.72 1.07, 2.76 1.54 0.91, 2.62  1.51 0.89, 2.56 
   3rd quintile 1.63 1.02, 2.59 1.59 0.94, 2.67  1.53 0.91, 2.58 
   4th quintile 0.92 0.54, 1.55 1.02 0.58, 1.81  1.03 0.58, 1.84  
   5th quintile 1.00  1.00   1.00  
   P (linear trend) <0.001  <0.001   0.001  
        
Hemoglobin        
   1st quintile 3.14 2.13, 4.62 1.66 1.05, 2.61  1.56 1.00, 2.47 
   2nd quintile 1.85 1.23, 2.78 1.36 0.86, 2.16  1.33 0.84, 2.12 
   3rd quintile 1.28 0.83, 1.98 1.27 0.78, 2.07  1.26 0.88, 2.05 
   4th quintile 1.33 0.86, 2.05 1.48 0.91, 2.42  1.48 0.91, 2.42 
   5th quintile 1.00  1.00   1.00  
  P (linear trend) <0.001  0.017   0.12  
        
Low BMI-and-chronic comorbidity 2.35 1.54, 2.58 1.93 1.15, 3.24  1.73 1.02, 2.95 
        
Model I: Unadjusted  
Model II: Adjusted for age, education, dyslipidaemia, hypertension, cardiovascular disease, stroke, diabetes, 
creatinine, smoking, alcohol, depression, self-rated health, physical functional status, leisure time activity level, 
APOE ε4 status.   
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Table 4  MMSE scores by Albumin, Hemoglobin, BMI and MICS categories in subset of participants with 




Mean ± SE 
Analysis of variance 
    
Albumin Quintiles   Overall F=2.862, 4df, P=0.022 
   1 (< 40 g/L) 388 27.67 ± 0.22 Linear contrast, P=0.002 
   2 (40-41 g/L)  470 27.87 ± 0.22 Quadratic contrast: P=0.56 
   3  (42-43 g/L) 546 27.86 ± 0.22  
   4  (44-45 g/L) 490 27.99 ± 0.22  
   5  (≥ 46 g/L) 358 28.02 ± 0.23  
    
Hemoglobin quintiles   Overall F=2.37, 4 df, P=0.05 
   1 (Men: <13.3g/dL; Women: <12.2 g/ dL)  377 27.90± 0.22 Linear contrast: P=0.56 
   2 (Men: 13.3-14.1 g/dL; Women 12.2-12.7g/dL) 445 27.97 ± 0.21 Quadratic contrast: P=0.99 
   3 (Men: 14.2-14.7g/dL; Women: 12.8-13.2 g/dL) 466 27.73 ± 0.22  
   4 (Men: 14.8-15.3g/dL; Women: 13.3-13.7g/dL) 441 27.99 ± 0.22  
   5 (Men: ≥15.4g/dL; Women: ≥13.8g/dL) 523 27.82 ± 0.22  
    
Low BMI-and-chronic comorbidity   Overall F=0.047, 1 df, P=0.83 
   Yes 124 27.90 ± 0.24  
   No 2128 27.86 ± 0.20  
    
 
* Adjusted for gender, age, education, dyslipidaemia, hypertension, cardiovascular disease, stroke, 
diabetes, creatinine, smoking, alcohol, depression, self-rated health, physical functional status, leisure time 








4.2 Study II:  Cross-sectional and longitudinal analyses of the relationships between 
serum albumin and global cognitive decline (measured by MMSE) and its effect 
modification by APOE-ε4. 
 
The mean age of the cohort was 66.0 (SD 7.3) years, 65% were women, and 51% had 6 
or less years of formal education. The mean serum albumin was 42.3 (SD 3.1) g/L, and 
the mean MMSE score was 27.2 (SD 3.2). Among the tertile groups of serum albumin, 
participants with low albumin were more likely to be older, less educated, smokers, and 
show poorer renal function, anemia and depressive symptoms (Table 5).  
 
Controlling for age, gender, education, medical comorbidity, hypertension, diabetes, 
cardiac diseases, stroke, smoking, alcohol drinking, depression, nutritional status, BMI 
(kg/m2), anemia, glomerular filtration rate, APOE-ε4 and baseline MMSE (in 
longitudinal analysis), (Table 6), decreasing levels of albumin was associated with 
increased risk of cognitive impairment in cross-sectional analysis (P for trend=0.002), 
and with cognitive decline in longitudinal analysis (P for trend=0.001). Using high 
albumin level (>44 g/L) as referent exposure, the OR of association of low albumin (<42 
g/L) with cognitive impairment was 2.34 (95% CI, 1.33-4.11, P=0.003), and with 
cognitive decline was 2.10 (95% CI, 1.41-3.12, P<0.001).   
 
The associations of albumin with cognitive status were also examined for participants 
stratified by their APOE-ε4 status (Table 6). We observed that the OR’s of association of 
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decreasing albumin with cognitive impairment and cognitive decline were elevated in 
both individuals with and without the APOE-ε4 allele, but the associations were much 
more pronounced in individuals with the APOE-ε4 allele (statistical interaction of APOE-
ε4 status and albumin for cognitive impairment, P=0.14; and for cognitive decline, 
P=0.04).   
 
To exclude the possibility that low albumin might be a result of poor cognitive 
functioning, we restricted the analysis to high-functioning participants who had baseline 
MMSE scores of 24 and above (Table 7), and found the same statistically significant 
associations between decreasing albumin levels and cognitive decline in the whole 
sample. Similar results of significant interactive effects of APOE-ε4 and albumin levels 
on cognitive decline were also observed (Table 7).  
  
Table 5 Baseline descriptive characteristics of participants by albumin categories 
 
 Albumin Categories (g/L)  
 Low (<42)  Medium (42-44)  High (>44)  
P value 
        
Sample size 648  616  390   
Age (yr), mean (SD) 67.6 (7.8)  65.2 (6.8)  64.4 (6.8)  <0.001 
Female Gender, %  67.4   63.3  63.6  0.25 
Education ≤6 yr, %  59.1  48.2  43.3  <0.001 
Number of medical comorbidity, %        
   None 9.4  8.8  7.2  
   1-2 49.4  50.6  47.7  
   ≥3 41.2  40.6  45.1  
0.53 
Hypertension, %  50.3  59.3  57.9  0.03 
Diabetes, %  15.6  15.3  18.7  0.30 
Cardiac diseases, % 8.6  6.8  6.7  0.36 
Stroke, % 4.2  4.1  2.3  0.25 
Smoking, % 8.3  4.9  2.3  <0.001 
Alcohol, % 7.4  7.8  6.9  0.89 
Depression (GDS≥5), %  14.1  7.2  13.9  <0.001 
APOE-ε4, %  20.1  16.7  16.9  0.24 
Nutritional risk (Nutrition Screening score ≥3), %  29.9  30.2  30.2  0.99 
BMI (kg/m2), mean (SD) 23.4 (3.7)  23.8 (3.5)  23.7 (3.3)  0.062 
Anemia (<12 in women, <13 in men), %  16.0  10.9  7.5  <0.001 
Glomerular Filtration Rate (GFR, ml/min, Cockroft formula), mean (SD)  61.3 (18.3)  65.3 (17.1)  66.1 (18.0)  <0.001 
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Table 6 Cross-sectional and longitudinal analyses of association of serum albumin level (in tertiles) with cognitive function  
    Cross-sectional analysis  Longitudinal analysis 









(95% C.I.) P 
           
Whole sample (N=1664)           
Low (<42g/L) 648 39.1 (1.7)  15.3 2.34 (1.33-4.11) 0.003  19.1 2.10 (1.41-3.12) <0.001 
Medium (42-44 g/L) 616 43.0 (0.8)  8.1 1.62 (0.89-2.93) 0.11  14.3 1.40 (0.93-2.09) 0.10 
High (>44 g/L) 390 46.3 (1.5)  4.9 1.00 P (trend)=0.002  11.0 1.00 P (trend)<0.001 
           
APOE-ε4 non-carriers (N=1355)           
Low (<42g/L) 518 39.2 (1.7)  14.7 1.88 (1.03-3.42) 0.039  18.9 1.79 (1.17-2.72) 0.007 
Medium (42-44 g/L) 513 42.9 (0.8)  8.6 1.50 (0.81-2.81) 0.20  13.6 1.15 (0.75-1.76) 0.53 
High (>44 g/L) 324 46.3 (1.5)  5.6 1.00 P (trend)=0.038  12.7 1.00 P (trend)=0.004 
           
APOE-ε4 carriers (N=299)           
Low (<42g/L) 130 39.2 (1.8)  17.7 10.2 (1.14-31.3) 0.038  20.0 7.49 (1.53-36.6) 0.013 
Medium (42-44 g/L) 103 43.1 (0.8)  5.8 2.65 (0.27-26.1) 0.40  17.5 5.40 (1.11-26.4) 0.037 
High (>44 g/L) 66 46.1 (1.5)  1.5 1.00 P (trend)=0.006  3.0 1.00 P (trend)=0.012 
            
Interaction: Albumin * APOE-ε4      0.14    0.04 
            
1 MMSE score ≤ 23 
2 Cognitive decline: at least 2-point drop in MMSE score during follow-up period;  
 
Adjusted for age (yr), gender, education (≤6 yr, >6 yr), number of medical comorbidity (none, 1-2, ≥3), hypertension, diabetes, cardiac diseases, 
stroke, smoking, alcohol drinking, depression (GDS ≥5), APOE-ε4, nutritional status (Nutrition screening score <3, ≥3), BMI (kg/m2), anemia 
(<12 in women, <13 in men), Glomerular Filtration Rate (GFR, ml/min, Cockroft formula); for cognitive decline: adjusted additionally for 
baseline MMSE and length of follow-up 
 
  
Table 7 Longitudinal association of serum albumin level (in tertiles) with cognitive decline1 in 
participants with MMSE≥24 at baseline  
 N % cognitive decline1  
Adjusted OR 2  
(95% C.I.) P 
Whole sample (N=1486)    
Low  549 20.6  2.14 (1.42-3.22) <0.001 
Medium 566 15.2  1.44 (0.96-2.18) 0.08 
High 371 11.3  1.00 P (trend)<0.001 
APOE-ε4 non-carriers (N=1217)    
Low  442 20.4  1.82 (1.18-2.81) 0.007 
Medium 469 14.7  1.20 (0.78-1.86) 0.40 
High 306 13.1  1.00 P (trend)=0.004 
APOE-ε4 carriers (N=269)    
Low  107 23.4  6.72 (1.29-34.9) 0.024 
Medium 97 17.5  4.54 (0.87-23.6) 0.07 
High 65 3.1  1.00 P (trend)=0.022 
      
Interaction: Albumin*APOE-ε4     0.049 
1 Cognitive decline: at least 2-point drop in MMSE score during follow-up period;  
2  Adjusted for age (yr), gender, education (≤6 yr, >6 yr), number of medical comorbidity (none, 1-2, ≥3), 
hypertension, diabetes, cardiac diseases, stroke, smoking, alcohol drinking, depression (GDS ≥5), APOE-
ε4, nutritional status (Nutrition Screening score <3, ≥3), BMI (kg/m2, anemia (yes/no; Glomerular 








4.3 Study III: Cross-sectional analyses of the independent associations between 
homocysteine, folate, vitamin B-12 and cognitive performance in community-dwelling 
elderly Chinese with generally well cognitive and physical functioning. 
 
The characteristics of the study population are summarized in Table 8 and Table 9. The 
mean age of the participants was 64.2 ± 6.7 years, and a larger proportion were females 
(60.2%). The mean number of years of education was 6.9 ± 4.4, and there were only 
small proportions of regular daily drinkers (10.3%) and smokers (ex-smoker and current 
smokers, 15.2%). Nearly half of the population had a history of hypertension (45.7%) 
and 12.3 % of them had diabetes. Altogether, 10.5% of the participants had a history of 
heart failure, heart attack, atrial fibrillation or stroke.       
 
Homocysteine was significantly correlated with folate (Pearson correlation r = -0.235, P 
< 0.001), vitamin B-12 (r = -0.210, P < 0.001), and creatinine (r = 0.494, P <0.001); the 














Table 8 Demographic and laboratory test characteristics of study participants  
Variable Mean ± SD (range) or Percentage 
Age  64.2 ± 6.7 (55 – 86) 
Sex (% female) 60.2 
Number of years of education 6.9 ± 4.4 (0 – 20) 
BMI (kg/m2) 23.7 ± 3.5 (12.5 – 40.6) 
Ex- or current smoker, % 15.2 
Regular alcohol drinker, % 10.3 
Hypertension, % 45.7 
Diabetes mellitus, % 12.3 
Cardiovascular disease, % 10.5 
GDS 1 total score 2.6 ± 3.0 (0 – 15) 
Total cholesterol (mmol/L) 5.5 ± 1.0 (2.9 – 9.3) 
Creatinine (µmol/L) 79.9 ± 24.2 (42 – 235) 
Homocysteine (µmol/L) 13.0 ± 4.6 (5.5 – 50) 
Folate (nmol/L) 24.9 ± 12.4 (6.7 – 90) 
Vitamin B12 (pmol/L) 397.8 ± 174.2 (35 – 1350) 
 










Table 9 Cognitive performance of study participants 




    
MMSE 1 total score  27.9 ± 1.7 24 – 30 
Digit span total raw score 451 15.9 ± 4.0 8 – 29 
Spatial span total raw score 386 12.0 ± 3.7 2 – 21 
RAVLT 2 immediate recall 3 402 43.4 ± 9.8 13 – 70 
RAVLT delayed recall  383 8.9 ± 3.3 0 – 15 
RAVLT verbal learning 4 402 7.2 ± 2.0 2 – 13 
RAVLT percentage of forgetting 5 382 24.4 ±  21.3 0 – 100 
VR 6 immediate recall total raw score 390 66.6 ± 18.4 11 – 102 
VR delayed recall total raw score 375 41.2 ± 20.9 0 – 100 
Categorical Verbal Fluency 385 42.5 ± 9.4 16 – 82 
Design Fluency condition I  337 7.0 ±  3.2 1 – 18 
Design Fluency condition II  335 7.7 ± 3.6 1 – 19 
Design Fluency condition III 335 5.1 ± 2.9 0 – 15 
SDMT 7 Written version 232 33.8 ± 13.9 4– 66 
SDMT Oral version 232 41.4 ± 14.6 7 – 74 
Trail Making Test  A (seconds) 92 49.4 ± 23.3 22 – 136 
Trail Making Test  B (seconds) 72 108.4 ± 55.0 43 – 333 
Block Design Total raw Score 103 24.4 ± 9.7 6 – 68 
 
1 Mini-Mental State Examination 2 Rey Auditory Verbal Learning Test 3 The sum of words correctly 
recalled through trial I to trial V 4 The maximum of words correctly recalled from trial I to trial V − words 
correctly recalled at trial I 5 100 × (words correctly recalled at trial V – words correctly recalled at delayed 




                                                                                                                                           
 
 
 In base models (I), log transformed homocysteine was inversely and significantly 
associated with Design Fluency II (Beta = -0.143), SDMT Written (Beta = -0.115), and 
Block Design total raw score (Beta = -0.296) (Table 10). In multivariable models that 
controlled for other covariates, homocysteine was significantly associated with two 
cognitive measures: Block Design (Beta = -0.319), and SDMT Written (Beta = -0.129), 
independently of a wide range of potential confounders (Model II, Table 11) as well as 
folate and B-12 (Model III, Table 11). 
 
Log transformed folate was significantly associated with each of RAVLT immediate 
recall, RAVLT delayed recall, RAVLT verbal learning, RAVLT percentage of 
forgetting, and Categorical Verbal Fluency in both base model I and Model II (Table 10 
and Table 12). In Model III, which controlled additionally for homocysteine and vitamin 
B-12, independent associations of folate with these cognitive scores remained 
significant, except for RAVLT immediate recall: RAVLT delayed recall (Beta = 0.139), 
RAVLT verbal learning (Beta = 0.112), RAVLT percentage of forgetting (Beta = -
0.139), Categorical Verbal Fluency (Beta = 0.104) (Table 12). 
 
Log transformed vitamin B-12 was not associated with any cognitive measure in all 















Table 10 Associations between natural log transformed homocysteine, folate, vitamin B-12 and 
cognitive test scores (model I) 1 
 
Homocysteine   Folate   B-12 
Cognitive test score Standardized  
β P 
 Standardized
  β P 
 Standardized
 β P 
                  
MMSE total score -0.080 0.073  0.076 0.063  0.056 0.17 
Digit span total raw score -0.054 0.252  0.041 0.339  0.067 0.12 
Spatial span total raw score -0.022 0.647  0.052 0.236  0.029 0.51 
RAVLT immediate recall -0.083 0.101  0.110 0.017  0.007 0.89 
RAVLT delayed recall  -0.074 0.188  0.149 0.003  0.045 0.37 
RAVLT verbal learning  -0.020 0.726  0.110 0.030  0.015 0.76 
RAVLT percentage of forgetting  0.051 0.373  -0.140 0.008  -0.069 0.19 
VR  immediate recall  0.006 0.905  0.069 0.103  0.045 0.29 
VR delayed recall  0.015 0.752  0.065 0.142  0.070 0.12 
Categorical Verbal Fluency -0.094 0.073  0.125 0.009  0.049 0.31 
Design Fluency (Condition I)  -0.080 0.127  0.013 0.786  0.054 0.26 
Design Fluency (Condition II)  -0.143 0.006  0.103 0.031  0.048 0.32 
Design Fluency (Condition III) -0.096 0.073  -0.002 0.961  0.026 0.59 
SDMT  Written -0.115 0.028  -0.030 0.526  0.073 0.13 
SDMT Oral -0.074 0.187  0.000 0.997  0.069 0.18 
Trail Making Test  A  -0.062 0.501  0.048 0.564  0.006 0.95 
Trail Making Test  B  0.057 0.642  -0.062 0.575  0.041 0.72 
Block Design Total raw Score -0.296 0.003  0.075 0.426  0.059 0.53 
                  
 
1 Model I Covariates: age, gender, number of years of education. 
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Table 11 Associations between natural log transformed homocysteine and cognitive test scores, 
adjusted for confounding in multivariable models 
 
Model I  Model II  Model III 
Cognitive test score 
Standardized 
β P  
Standardized 
β P  
Standardized 
β P 
SDMT  Written -0.115 0.028  -0.125 0.025  -0.129 0.031 
Block Design Total raw Score -0.296 0.003  -0.299 0.005  -0.319 0.006 
Design Fluency (Condition II)  -0.143 0.006  -0.140 0.013  -0.113 0.062 
 
Model I Covariates: age, gender, number of years of education. 
Model II Covariates: age, gender, number of years of education, cigarette smoking, alcohol consumption, 
Body Mass Index, total cholesterol, hypertension, diabetes, cardiovascular diseases, log transformed 
creatinine, GDS total score. 
Model III Covariates: log transformed homocysteine, folate and vitamin B-12 entered simultaneously with 
all covariates in model II.  
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Table 12 Associations between natural log transformed folate and cognitive test scores, adjusted for 
confounding in multivariable models 
 
Model 1  Model II  Model III 







RAVLT immediate recall 0.110 0.017  0.096 0.039  0.089 0.067 
RAVLT delayed recall  0.149 0.003  0.138 0.008  0.139 0.010 
RAVLT verbal learning  0.110 0.030  0.103 0.047  0.112 0.038 
RAVLT percentage of forgetting  -0.140 0.008  -0.142 0.008  -0.139 0.013 
Categorical Verbal Fluency 0.125 0.009  0.119 0.016  0.104 0.042 
Design Fluency (Condition II) 0.103 0.031  0.096 0.050  0.068 0.175 
 
Model I Covariates: age, gender, number of years of education. 
Model II Covariates: age, gender, number of years of education, cigarette smoking, alcohol consumption, 
Body Mass Index, total cholesterol, hypertension, diabetes, cardiovascular diseases, log transformed 
creatinine, GDS total score. 
Model III Covariates: natural log transformed homocysteine, folate and vitamin B-12 entered 









4.4 Study IV: Cross-sectional analysis of the role of APOE ε4 as a genetic predisposing 
factor modulating the effect of B-12 on cognitive function in community-dwelling elderly 
Chinese with “normal” cognitive functioning. 
 
Various characteristics of the study participants are summarized in Table 13. The mean 
age of the study population was 63.9 and 64.2% were females. The average number of 
years of education was 7.2. There was small proportion of smokers (14.7%) and regular 
alcohol drinkers (5.1%). The mean concentration of vitamin B-12 was 403 pmol/L. At 
least one APOE ε4 allele was found in 62 (15.1%) of the participants.  
 
There was no significant association between vitamin B-12 and any cognitive test scores 
in the whole study sample (data not shown), and for non- APOE ε4 allele carriers (Table 
14). However, in APOE ε4 carriers, log transformed vitamin B-12 was positively and 
significantly associated with MMSE total score (Beta=0.33, P=0.01), Digit span 
backward longest sequence (Beta=0.43, P=0.002), RAVLT immediate recall (Beta= 
0.29, P= 0.05), Visual Reproduction immediate recall (Beta= 0.24, P= 0.03). The 
negative association between log transformed vitamin B-12 and log transformed Trail 
Making Test B was borderlinely significant (Beta=-0.68, P=0.06). Interaction term was 
significant for Digit span backward (P=0.01), RAVLT immediate recall (P=0.01), log 
transformed TMT-B (P=0.04), and borderlinely significant for MMSE (P=0.06).  
 
When low vitamin B-12 was examined as a dichotomous threshold variable in non-linear 
relationships, similar significant relationships of B12 with MMSE, Digit Span backward, 
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and RAVLT immediate recall in APOE ε4 carriers were found. (Table 15) Taking 
MMSE as an example, low vitamin B-12 (lower than 251 pmol/L) compared to normal 
B-12 was associated with nearly 1.8 point score decrease in MMSE score in APOE ε4 
carriers, while there was almost no difference between them in non-APOE ε4 carriers. 
The interactions terms of B12 and APOE ε4 were significant: for MMSE total score 
(F=7.3, P=0.007, η2=0.02), Digit Span backward (F=7.8, P=0.006, η2=0.02), and 
RAVLT immediate recall (F=5.9, P= 0.02, η2=0.02). 
 
Table 13 Baseline characteristics of the study sample  
 
Variable   Mean / N SD / Percentage  Range 
        
Age  63.9 6.6 55-87 
Female  255 64.2  
Education years 7.2 4.5 0-22 
Ex- and current smokers 60 14.7  
Alcohol drinkers  21 5.1  
Hypertension 181 44.1  
Diabetes 53 12.9  
Vascular diseases 44 10.8  
APOE ε4 allele carrier 62 15.1  
Vitamin B12 (pmol/L) 403 188.3 35-1476 
MMSE1 total score 27.8 1.7 24-30 
        
 
Mean, SD, and range for continuous variables 
N and Percentage for dichotomous variables 
 
Alcohol drinker was defined as >= 1 drink/wk, vascular disease was defined as any of the following: 
stroke, heart attack, heart failure, artrial fibrillation. Hypertension and diabetes were based on self-reported 
medical history. 
 
1. Mini-Mental State Examination  
 
 Table 14 Natural log-transformed vitamin B-12, APOE ε4, and cognitive performance  
 
      No-ε4      ε4      
Cognitive test score   N Beta P    N Beta P  P for  interaction 
                      
MMSE1 total score  349 0.02 0.76  62 0.33 0.01  0.06 
Digit span forward longest sequence  335 0.09 0.11  58 0.16 0.29   
Digit span backward longest sequence  334 0.04 0.39  57 0.43 0.002  0.01 
Spatial span forward longest sequence  291 -0.02 0.68  50 0.13 0.35   
Spatial span backward longest sequence  290 0.06 0.24  49 0.14 0.35   
RAVLT2 immediate recall  311 -0.06 0.29  52 0.29 0.05  0.01 
RAVLT delayed recall   295 -0.02 0.78  49 0.20 0.21   
VR3  immediate recall   300 0.02 0.71  51 0.24 0.03  0.58 
VR delayed recall   288 0.03 0.51  48 0.17 0.21   
Categorical Verbal Fluency  292 0.04 0.52  50 0.26 0.09  0.20 
Design Fluency condition I   255 0.06 0.24  44 0.04 0.83   
Design Fluency condition II   255 0.05 0.38  44 0.08 0.59   
Design Fluency condition III  255 0.04 0.44  43 0.22 0.16   
SDMT4  Written version  174 0.04 0.44  27 0.25 0.09  0.18 
SDMT Oral version  174 0.02 0.66  27 0.24 0.18   
Trail Making Test A (Log transformed)  76 0.04 0.68  14 -0.37 0.21   
Trail Making Test B (Log transformed)  65 0.15 0.21  9 -0.68 0.06  0.04 
Block Design total score  71 0.11 0.39  12 0.05 0.92   
                      
 
Variables in the model for stratified analysis (ε4, non- ε4): age, gender, number of years of education, cigarette smoking, alcohol consumption, hypertension, 
diabetes, vascular diseases, and natural log-transformed vitamin B-12. The significance of interaction (Ln B-12x APOE ε4) was tested in the whole population, 
with all above variables, APOE ε4 status, and interaction term in the models. 
 
  1 Mini-Mental State Examination; 2 Rey Auditory Verbal Learning Test; 3 Visual Reproduction; 4 Symbol Digit Modality Test 
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Table 15 Low vitamin B-12, APOE ε4 status, and cognitive performance  
 
Cognitive test score  
No-ε4 and 
Low B-12  
No-ε4 and Normal 
B=12   
ε4 and  Low 
B-12  
ε4 and Normal  
B-12  Interaction 
  Mean SE  Mean SE  Mean SE  Mean SE  F P  η2 
 
MMSE1 total score  27.6 0.3  27.9 0.2  26.4 0.5  28.2 0.3  7.3 0.007 0.02 
Digit span backward longest sequence  4.4 0.2  4.5 0.2  3.6 0.4  5.0 0.2  7.8 0.006 0.02 
RAVLT2 immediate recall  44.4 1.8  42.3 1.5  38.2 3.2  44.6 1.9  5.9 0.02 0.02 
                                  
 
Low B-12 was defined as vitamin B-12 <251 pmol/L 
 
Variables in the model: age, gender, number of years of education, cigarette smoking, alcohol consumption, hypertension, diabetes, vascular diseases, low 
vitamin B-12, APOE ε4, and interaction between low B-12 and APOE ε4. 
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CHAPTER 5 DISCUSSION 
5.1 Study I 
The results of our study suggested that low albumin levels (below 40 g/L in the lowest 
quintile of the population distribution), low hemoglobin (<12.2g/dL in women and <13.3 
g/dL in men), and being underweight (BMI <18.5kg/m2) together with having one or 
more chronic morbid conditions were independent risk factors of poor cognitive 
performance in older persons.  
 
In case-control study (19), serum albumin has been reported to be decreased in patients 
with late-onset Alzheimer’s disease compared to controls, but it is possible that serum 
albumin might be lowered as a result of poor feeding due to the underlying cognitive 
impairment. The association of low albumin and cognitive impairment observed in our 
cross-sectional study is also participant to the same limitation in causal inference. 
However, we were able to show that in cognitively better functioning older adults; there 
was an inverse linear relationship of albumin concentrations and MMSE performance. A 
previous study (23) has also reported a cross-sectional association of low albumin with 
MMSE scores in the whole sample, but not when participants with MMSE scores <21 
were excluded. Our result however was based on a larger sample size and stricter 
exclusion criteria for MMSE at ≤23, and hence was more robust. Our results agree with 
those of other investigators who showed in longitudinal studies that serum albumin was 
associated with cognitive decline (22).   
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 Studies investigating the association of anemia with cognitive decline and dementia risk 
have given mixed results (26-31). Case control (26, 29, 30) and longitudinal studies have 
reported increased odds of association with anemia with dementia or Alzheimer’s disease 
(27) or cognitive decline (31) or failed to show an association (26). Cross-sectional 
studies of community-living elderly have variously reported a linear relationship (28) or a 
U-shaped relationship (30). Our results support a relationship of hemoglobin with 
cognitive performance, but we did not observe a U-shaped relationship. Albumin was not 
investigated concurrently in these studies. Our results based on community sample of 
older adults agree with a study of chronic heart failure a (CHF) patients that has reported 
that both anemia and low serum albumin were independently associated with cognitive 
impairment in multivariable analysis (21). 
 
We observed that, in the presence of low albumin and low hemoglobin, underweight 
(BMI below 18.5kg/m2) by itself did not appear to be an independent risk marker of poor 
cognitive performance. However, being underweight while having one or more chronic 
comorbidities together appeared to be a significant risk marker. This variable may be a 
surrogate indicator for body mass loss associated with the presence of chronic diseases. 
Its association with poor cognitive performance in this study is also consistent with 
reported observations of significant weight loss associated with a diagnosis of dementia 
and the high prevalence of cognitive impairment in association with cachexia in patients 
with congestive heart and renal failure (21, 28, 106).  
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 There is increasing evidence that inflammatory mechanisms are involved in the 
pathogenesis of dementia and Alzheimer disease (AD) (107). Chronic systemic low-
grade inflammation may be the common factor mediating the relationships between these 
nutritional markers with cognitive impairment. In older persons, systemic inflammatory 
activity is increased by the contributions of genetic factors, smoking, infections, obesity 
and declining sex hormone activities, and exacerbated by the presence of age-associated 
diseases. Although low serum albumin and haemoglobin are conventionally regarded as 
biochemical and haematological markers of protein-calorie malnutrition, they are also 
involved in chronic systemic inflammation. Albumin is a negative acute-phase protein 
whose plasma concentration in patients with chronic diseases typically decreases in 
response to systemic inflammation (9). Anemia in individuals with chronic disease is the 
result of suppressed erythropoiesis by systemic inflammation (108). In the presence of 
chronic diseases, low body mass index (BMI) results when there is preferential loss of 
skeletal muscle mass (sarcopenia), as well as fat tissues and bone mass, and is a 
manifestation of chronic inflammatory activities that characterize cachexia and chronic 
diseases (109). The combination of malnutrition and systemic inflammation in older 
persons has been termed ‘malnutrition–inflammation complex syndrome’ (MICS) (110) 
and is well described in cachexic patients with chronic heart failure, renal failure, 
diabetes, COPD, cancers, severe infections, injury and geriatric conditions. Low albumin, 
anemia and body mass losses are the most commonly observed in these conditions.   
 
Our quintile cut-off values of low albumin (40g/L) and low hemoglobin (12.2g/dL in 
women and 13.3g/dL in men) approximate the conventional cut-offs used clinically to 
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 define hypoalbuminemia (35g/L) and anemia (12.g/dl in women and 13g/dl in men). 
Similar results were obtained in re-analysis using clinical cut-off of albumin <35g/L. Our 
findings suggest that the identification of hypoalbuminemia, anemia and loss of body 
mass in the elderly may be useful in the early detection and treatment of cognitive 
impairment and dementia. There is a limited amount of evidence suggesting that in 
patients with chronic heart failure, cancer and stroke, restoration of hemoglobin levels 
and albumin (21, 111) was associated with improved cognitive function.  
 
Because the cross-sectional design of our study precludes firm inferences about causal 
relationship, longitudinal studies should further investigate cognitive declines and 
whether the correction of hypoalbuminemia, anemia and body mass loss in community-
living elderly persons in primary care have a significant impact on improving cognitive 
status.  
 
5.2 Study II 
Our findings suggest that decreasing serum albumin within the ‘normal’ range of values 
in community-living older adults are associated with increased risk of cognitive 
impairment and decline, independent of other risk factors for cognitive decline. Very few 
studies have reported such an association. In a case-control study (19), serum albumin 
has been reported to be decreased in patients with late-onset Alzheimer’s disease 
compared to controls. In hospital inpatients (20, 21), low albumin was also reported to be 
associated with cognitive impairment.  
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 The Longitudinal Aging Study in Amsterdam showed in cross-sectional analysis an 
inverse association of albumin with MMSE scores at baseline (23) in the whole sample, 
but not when participants with MMSE scores <21 were excluded. In their longitudinal 
analysis, albumin was found not to be associated with cognitive decline. The New 
Mexico Aging Process study was the only other study that reported a correlation of serum 
albumin both concurrently and longitudinally with scores on logical memory (22).  
 
In cross-sectional analyses, the observed association may be explained by low albumin 
being the result of poor nutritional status in cognitively-impaired and demented elderly. 
However, in our study, this did not appear to explain the association of low albumin 
levels with cognitive decline observed in further analyses with cognitively high-
functioning participants. Nevertheless, it is still possible that in cognitively intact elderly, 
low albumin may accompany reducing food intake and increased loss of weight that 
characterize pre-clinical stages of dementia (38, 112).    
 
We also found that the presence of the APOE-ε4 allele significantly increased 
multiplicatively the odds of association of albumin with cognitive impairment and 
decline. No previous studies have reported such an effect modification by APOE-ε4. Our 
results suggested that the APOE-ε4 genotype might represent a susceptibility factor that 
increased the risk of cognitive impairment and decline in individuals with low albumin.  
 
Multiple biological mechanisms explain the association of albumin with cognitive 
impairment and decline. Increased age-related cognitive decline is a precursor of the 
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 development of dementia of the Alzheimer’s disease and vascular types, and chronic low-
grade inflammation and cytokines play a causal role (113). In response to increased 
systemic inflammatory activity due to genetic factors, smoking, obesity, declining sex 
hormones, infections and age-associated diseases, plasma concentration of albumin 
typically decreases, hence its status as a negative acute-phase protein. In tissue damage 
and at sites of inflammation, cytokines, such as tumour necrosis factor-alpha, interleukin-
1 and interleukin-6, depress albumin synthesis, increase its degradation and increase 
capillary permeability and escape of intravascular albumin (114). 
 
The increased extracellular fluid content of albumin and other proteins prevent excessive 
oxidant damage, because albumin is an important anti-oxidant at physiological pH (11), 
inhibiting copper-dependent generation of free hydroxyl radicals and lipid peroxidation, 
scavenging peroxy radicals, and decreasing lipoxygenase activity, binding free fatty acids 
and protecting them from peroxidation. In the CNS, increased CSF concentrations of 
albumin provide metal-binding antioxidant protection against metals like copper and iron 
which accelerate free radical reactions. Albumin is considered to be a ‘sacrificial’ 
antioxidant (11), and within limits, the damage from free radicals attack are biologically 
insignificant because of its high concentration, rapid turnover through proteolytic 
degradation and replacement (115). In chronic inflammatory diseases, albumin is 
typically lowered in the plasma. Plasma albumin is grossly reduced when chronic 
diseases induce anorexia and malnutrition, and is nearly always present in sarcopenia, 
frailty and cachexic states, in which pro-inflammatory cytokines feature prominently 
(109).  
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There is increasing evidence that inflammatory mechanisms are involved in the 
pathogenesis of dementia of both Alzheimer disease and vascular types [108]. 
Proinflammatory cytokines and acute-phase reactants are increased in the CSF and 
peripheral blood of patients with Alzheimer’s disease (AD) (116). Next to AD, 
cerebrovascular disease is the most common cause of dementia, and degenerative and 
vascular damage often coexist in the brain of older patients with dementia (117). Chronic 
vascular inflammation is a key pathogenetic process of atherosclerosis (118). Since 
albumin reduces platelet aggregability and directly protects vascular endothelial cells 
from apoptotic cell death (119), low albumin is also linked to an increased risk of 
cardiovascular diseases. Quantitatively albumin is the most important source of thiol 
group (120) which can bind covalently to and inhibits the degradation of nitric oxide, 
making it a potential nitrovasodilator that modulates coronary disease and other vascular 
processes. Low level of albumin may thus be a marker of atherosclerotic and vascular 
risk of developing cognitive impairment and dementia.   
 
Apolipoprotein E is a polymorphic protein which has critical functions in redistributing 
lipids among CNS cells, repairing injured neurons, maintaining synapto-dendritic 
connections, and scavenging toxins (84). Structural and functional neuroimaging studies 
indicate that in non-demented individuals, the APOE-ε4 genotype was associated with 
greater hippocampal volume loss (121, 122), and a greater magnitude and extent of brain 
activation during a challenging memory task in the prefrontal cortex, hippocampus, and 
parietal cortex (123, 124). It is thus plausible that in APOE-ε4 carriers, their 
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 compromised neuroanatomical reserves may combine with multiple pathophysiological 
factors associated with low albumin on neural processes in depleting cognitive reserves 
and lower the threshold at which cognitive deficits occur. 
 
Low albumin level may be a general biomarker of various underlying pathophysiological 
processes including chronic inflammatory activity, oxidative stress, atherosclerotic risk 
and micronutrient deficiencies that combine to undermine cognitive functioning in older 
adults. Our results suggest that the observed association of low albumin with cognitive 
decline was independent of vascular risk factors and diseases and poor nutritional status, 
and was evident also in cognitively high-functioning older adults. Whether low albumin 
concentration is an independent "risk factor" with a direct pathophysiological role in the 
development of cognitive decline cannot be established from this study. Randomized 
controlled trails should confirm the effects of increased albumin intake on cognitive 
function in hypoalbuminaemic elderly.  
 
A large body of evidence (12) suggests that albumin concentration is a highly sensitive 
and widely applicable prognostic indicator of preclinical disease and disease severity, as 
well as primary or secondary malnutrition. It is inexpensive and easily obtainable and 
provides prognostic information over its entire range of ‘normality’. Serum albumin may 
thus be also used as a marker of increased risk of cognitive decline and early dementia. 
Pending confirmatory studies from more longitudinal follow up studies and randomized 
controlled trials; our finding also suggests that the screening and treatment of elderly 
people low albumin may be selectively targeted at those with the APOE ε4 genotype.   
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5.3 Study III 
Our results based on a community sample of Chinese older adults with generally well 
global cognitive and physical functioning suggest that homocysteine and folate may have 
independent and differential associations with specific domains of cognitive function. 
Homocysteine appeared to be specifically associated with constructional ability and 
information processing speed; folate appeared to be associated specifically with episodic 
memory and language ability. These associations were independent of a wide range of 
confounding factors and also of each other.  
 
With regard to executive control function measured with Design Fluency, no clear 
statistically significant associations with homocysteine or folate were observed, although 
the marginally significant associations shown in several models do not rule out this 
possibility.  There was also no association with Categorical Verbal Fluency. With regard 
to vitamin B-12, there was no observable significant association with performance on any 
cognitive test.  
 
Our results in a Chinese population support similar associations of homocysteine and 
folate with cognitive performance reported in Western studies, even though there might 
be subtle differences between different ethnic populations. A few previous studies have 
also reported patterns of specific cognitive domains that are differentially associated with 
homocysteine and folate. In a small group of 70 male elderly participants, the Normative 
Aging Study found that higher concentration of homocysteine was specifically associated 
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 with poorer spatial copying skills while B vitamins were more strongly associated with 
memory performance (49). The Sacramento Area Latino Study on Aging also found that 
in elderly Latinos, homocysteine was inversely associated with performance on 3MSE, 
picture association, verbal attention span, and pattern recognition, while folate was 
associated with 3MSE and delayed recall (56, 61). However, individual 
neuropsychological tests may assess overlapping cognitive domains to varying extents, 
and studies using different test battery make cross comparison of results difficult.   
 
Because of our strict exclusion criteria and rigorous control of potential confounding, our 
results may possibly be biased by over-adjustment towards demonstrating null 
associations. Hence, marginally significant associations should not be dismissed. On the 
other hand, with numerous neuropsychological variables and multiple significance 
testings, a number of statistical tests may be expected to give spurious significance at the 
conventional alpha level of P<0.05. Lastly, the cross-sectional design of our study cannot 
firmly establish cause-and-effect relationship. Further longitudinal studies are warranted. 
.  
In our study, the lack of an observable association between vitamin B-12 and 
performance on any cognitive test suggests a less important role for vitamin B-12 than 
homocysteine and folate. However, the assessment of cobalamin status using serum 
vitamin B-12 may have limitations. Methylmalonic acid and holotranscobalamin are 
proposed to be more sensitive markers for vitamin B12 deficiency (43, 125).  In the study 
reported by Refsum et al, low holotranscobalamin was associated with Alzheimer’s 
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 disease even though total cobalamin was not (126). Hence, our study does not exclude a 
possible association with vitamin B-12.   
 
It is interesting to discuss why homocysteine and folate can exert separate effects on 
cognitive function. Although homocysteine is viewed as a marker of folate deficiency, its 
concentration is affected by multiple factors (42). In our study population, the correlation 
between homocysteine and folate is moderate (r = -0.235), making it possible to analyze 
their differential effects. Folate provides the methyl group for the conversion of 
methionine to S-adenosylmethionine (SAM), which is the major methyl donor for most 
methyltransferase reactions; thus folate deficiency can cause hypomethylation (127). 
Elevated homocysteine is postulated to affect the brain through vascular or neurotoxic 
mechanism (64, 128). Folate deficiency, on the other hand, may affect brain function 
either through high homocysteine (as an intermediary) or alternatively with decreased 
SAM, or both (128). Our results favour the involvement of both pathways and the 
differential effect of each mechanism. Protein synthesis in the brain is an essential 
process for the encoding of information in episodic memory and it is conceivable that the 
B vitamin-related memory deficits could be due to alterations in brain protein metabolism 
(129). We noted that with a wide range of cognitive domains measured, association 
between folate and cognition appears confined to episodic memory performance, thus our 
results suggest that this is plausible.  
 
Although conclusive evidence from randomized controlled trials is still insufficient, it is 
nevertheless possible that modification of homocysteine and B vitamin status could delay 
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 cognitive decline or even enhance cognitive function in elderly individuals. 
Observational studies of community-dwelling elderly showed that the rate of change of 
homocysteine concentration was significantly correlated with the rate of change of the 
Stroop scores (130). More recently, the Hordaland Homocysteine Study found a 
“favourable” change in folate or homocysteine concentrations over time is associated 
with better memory performance (62). Large scale clinical trials with longer 
interventional period are needed  
 
5.4 Study IV 
We found in this population-based sample of non-demented older adults that the effect of 
vitamin B-12 on cognitive performance was modified by APOE genotype. Vitamin B-12 
was significantly associated with several measures of cognitive function only in APOE ε4 
carriers. A significant interaction between low vitamin B-12 and APOE genotype was 
found for MMSE total score, Digit span backward, and RAVLT immediate recall.  
 
We have found only one previous investigation that has examined the interactive effect of 
vitamin B-12 and APOE genotype on cognitive function (87, 88). In that study of very 
old people aged over 75, no associations between low vitamin B-12 and APOE- ε4 allele 
were identified in respect to short-term memory or visuospatial skills, but an association 
was found for free recall as well as for dated face recognition, under demanding task 
conditions. These results suggest that the possession of the ε4 allele rendered encoding 
operations in free recall and retrieval operations in face recognition more vulnerable to 
the deleterious effects of low B vitamin levels.  
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 Our results based on Chinese older adults are generalizable to a more broadly 
representative study population. We confirmed the interaction between vitamin B-12 and 
APOE genotype regarding episodic memory (measured by RAVLT immediate recall in 
our study). Furthermore, we also found significant interaction for global cognitive 
function (measured by MMSE) and attention/working memory (measured by Digit span 
backward). Our findings suggest that individuals with genetic risk factors are more prone 
to the influence of vitamin B-12 status, and the interactive effect is not limited to episodic 
memory.  
 
Because there was only small numbers of subjects with low vitamin B-12 and APOE ε4 
allele carrier state, and limitations of sample size for some cognitive tests, the power to 
detect more significant interactions is limited in this study. For example, in the study 
sample for Trail Making Test B, there were only 9 APOE ε4 carriers, and among those 9 
APOE ε4 carriers, only 1 subject was classified in low vitamin B-12 group based on 
250/251 cut-off. Hence, we were unable to look at the interaction of low vitamin B-12 
and APOE ε4 on Trail Making Test B performance given such a situation. 
 
The exact mechanisms by which APOE-ε4 modulate the effects of vitamin B-12 on 
cognitive function are unclear, but are possibly explained in terms of current 
hypomethylation and homocysteine hypotheses related to vitamin B-12 effects, and 
neuroanatomical structures and functions that are compromised in APOE-ε4 individuals.  
Structural and functional neuroimaging studies indicate that in non-demented individuals, 
the APOE ε4 genotype was associated with greater hippocampal volume loss (121, 122), 
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 and a greater magnitude and extent of brain activation during a challenging memory task 
in the prefrontal cortex, hippocampus, and parietal cortex (123, 124). Healthy APOE-ε4 
carriers also showed reduced brain white matter integrity as compared with noncarriers 
(131). It is thus plausible that in APOE-ε4 carriers, their compromised neuroanatomical 
reserves may make them more vulnerable to environmental factors that could affect the 
brain. Along this line of argument, a number of epidemiologic studies have shown that 
the ε4 allele amplifies the effects of multiple risk factors for cognitive dysfunctions (132-
134), including vitamin B-12 (87, 88). 
 
Another line of evidence suggests that since Apolipoprotein E has isoform-specific 
effects on neuronal repair and remodelling (84, 135, 136), the ability to recover from the 
potentially reversible effects of vitamin B-12 may differ by APOE genotype. It has also 
been shown that subclinical low vitamin B-12 was associated with increased rate of brain 
volume loss, possibly through disturbing the integrity of brain myelin or inflammation 
(137). It is thus logical to postulate that the interplay between vitamin B-12 and APOE ε4 
might be more than a simple combination.  
 
Additionally, there was also reports suggesting that there is an interaction between APOE 
ε4 and homocysteine on cognitive performance (138), and homocysteine lowering with 
B-vitamins has been shown to be effective on lowering circulating level of  plasma Aβ40 
(139). Since decreased vitamin B-12 is accompanied with increased plasma total 
homocysteine, we cannot rule out the possibility that the observed interaction in our 
present study might be partly due to homocysteine.  
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It is possible that individuals with dementia may be prone to vitamin B-12 deficiency 
because of poor eating and diminished nutrient intake. To exclude this possibility in this 
study, we have eliminated a big proportion (26.8%) of subjects based on baseline MMSE, 
IQCODE, and follow-up MMSE scores. Most if not all participants who were incipient 
cases of mild or early dementia, including those with mild cognitive impairment, were 
likely to have been excluded. 
 
We also adjusted for a large number of potential confounding factors in multivariable 
analyses. Thus, the observed associations appeared robust, although given the cross-
sectional design of our study, we remain cautious about drawing definite causal 
inferences.  
 
A limitation in our measurements was that serum B12 was measure done only at one 
point in time, and serum vitamin B-12 alone may not be a sensitive enough measure of 
cobalamin status. Other elaborate laboratory tests (methylmalonic acid and 
holotranscobalamin) have been recommended (43, 125), but were not measured in our 
study. This was a possible drawback of our study because more subtle associations might 
have been present but were not detected.  Despite this, we were able to demonstrate 
significant interaction effects for vitamin B-12 and APOE on the more robust 
relationships with some cognitive performance.    
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 Most previous studies investigating the relationship between vitamin B-12 and cognitive 
function have revealed negative results, but a few have reported positive associations. As 
with most previous studies, we found no apparent relationship with any cognitive test 
performance in the whole sample analysis of data in our group of Chinese older adults. 
The prevalence of APOE ε4 allele carrier state was 15.1% in our population sample. 
Because almost all studies have not explicitly examined APOE genotype as a modulating 
factor in this relationship, the varying prevalence of the APOE ε4 allele in different 
populations could possibly explain these inconsistent findings. In populations with higher 
proportions of APOE ε4 carriers, the probability of finding a significant main effect of 
vitamin B-12 on cognitive function is greater. By the same token, negative results from 
randomized controlled trials could be expected to be due to unselective inclusion of 
subjects with respect to APOE ε4 carrier status. We thus hypothesize that vitamin B-12 
supplementation may be demonstrated to have differential clinical benefits for APOE ε4 
carriers and non-carriers.   
 
Our study adds to a growing list of studies that have reported significant interactions of 
APOE ε4 genotype with other environmental risk factors for cognitive decline. The 
practical significance of establishing a gene-environment interaction is that possible 
intervention measures can be selectively considered for those with the genetic 
predisposition. Pending confirmatory studies from more longitudinal follow up studies 
and randomized controlled trials, our finding suggests that special attention to cobalamin 
status and treatment may thus be selectively targeted at elderly people with the APOE ε4 
allele genotype.   
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CHAPTER 6 SUMMARY AND CONCLUSION 
 
In a series of studies (Study I to Study IV), using data collected from the Singapore 
Longitudinal Ageing Study, we investigated the relationship between nutritional factors 
(including albumin, hemoglobin, low body mass index, homocysteine, folate, and vitamin 
B-12) and cognitive performance and possible effect modification by Apolipoprotein E 
genotype among Asian older adults aged 55 and above. 
 
In Study I, we examined the independent associations of low albumin, low hemoglobin 
and low body mass index with global cognitive performance (measured by MMSE). In 
study II, we further explored the relationship between serum albumin and cognitive 
decline and its effect modification by Apolipoprotein E (APOE) ε4 status. In Study III, 
we examined the independent association between plasma total homocysteine, serum 
folate, serum vitamin B-12 and cognitive function (measured by a comprehensive 
neuropsychological test battery that assesses a wide range of cognitive domains) in 
community-dwelling Chinese elderly with generally good cognitive function and physical 
function. In Study IV, we further investigated the role of Apolipoprotein E (APOE) ε4 as 
a genetic predisposing factor modulating the effect of vitamin B-12 on cognitive 
function. 
 
In Study I, in multivariable analyses that controlled  age, gender, education, and vascular 
risk factors, low albumin in the bottom quintile (OR, 2.04; 95%CI, 1.22-3.41) and low 
hemoglobin in the bottom quintile (OR, 1.56; 95%CI, 1.00-2.47) and low BMI-with-
chronic comorbidity (OR, 1.73; 95%CI, 1.02-2.95) were independently associated with 
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 poor cognitive performance (MMSE ≤ 23). Among cognitively intact participants 
(MMSE ≥24), albumin concentration showed a significant inverse linear relationship 
with MMSE scores (P for trends <0.002).   
 
For Study II, in cross-sectional and longitudinal analyses that controlled a wide range of 
covariates, decreasing levels of albumin were associated with an increased risk of 
cognitive impairment (P for trend=0.002), and with cognitive decline (P for trend=0.001). 
Among participants who were cognitively intact at baseline (MMSE≥24), similar 
associations were observed (P for trends <0.001). APOE- ε4 modified the association (P 
for interaction=0.049); the association between low albumin and cognitive decline was 
more pronounced in individuals with the APOE-ε4 allele (OR=6.72, 95% CI=1.29-34.9) 
than in individuals without APOE-ε4 allele (OR=1.82, 95% CI=1.18-2.81). 
 
In study III, we found that Log transformed homocysteine was inversely associated with 
performance on Block Design (β = -0.319, P=0.006) and Symbol Digit Modality Test 
written version (β= -0.129, P=0.031). The Log transformed folate was significantly 
associated with Rey Auditory Verbal Learning Test delayed recall (β= 0.139, P=0.010), 
verbal learning (β= 0.112, P=0.038), percentage of forgetting (β= -0.139, P=0.013) and 
Categorical Verbal Fluency (β = 0.104, P=0.042). These results support differential 
associations of homocysteine and folate with specific domains of cognitive performance. 
 
Vitamin B-12 was not significantly associated with any cognitive test score in Study III.  
However, in Study IV, it was found that Low vitamin B-12 was associated with poorer 
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 performance on several cognitive measures in APOE ε4 allele carriers but not in non-
APOE ε4 carriers. The interaction between low B-12 (defined as vitamin B-12<251 
pmol/L) and APOE ε4 was significant for MMSE (F=7.3, P=0.007, η2=0.02), Digit Span 
backward (F=7.8, P=0.006, η2=0.02), and RAVLT immediate recall (F=5.9, P=0.02, 
η2=0.02).  
 
All these results support the important role of nutritional factors in cognitive performance 
and cognitive decline among older adults.  Findings from Study II and Study IV also 
suggest that the presence of APOE-ε4 allele could further potentiate these relationships. 
Multiple biological pathways may be involved in the observed associations. With regard 
to the interaction between low albumin, low vitamin-B12 and APOE-ε4, it may be due to 
compromised neuroanatomical and cognitive reserves of APOE ε4 allele carriers; older 
adults with one or more ε4 alleles could be more prone to detrimental nutritional factors 
compared with non-carriers. 
 
Our findings suggest that nutritional factor is a promising area to investigate in dementia 
and cognitive ageing research.  Albumin, hemoglobin and body mass index may be used 
as nutritional risk markers for screening and treating cognitive impairment in primary 
care. Lowering plasma homocysteine and optimizing B-vitamins concentration could be 
an effective measure for the primary prevention of dementia. However, these should be 
confirmed by conducting randomized controlled clinical trials.  
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 These findings should be interpreted with caution because of methodological limitations. 
An important limitation is its cross-sectional study design (Study I, Study III, and Study 
IV). It is possible that the observed association could simply reflect the poor nutritional 
status of early dementia patients; hence these measures we examined might be the 
markers of the very early stage of dementia rather than the causes. However, the 
exclusion of cognitive impaired participants in data analysis make the contamination of 
early dementia less possible. Additionally, a significant relationship between albumin and 
cognitive decline was revealed in the longitudinal analysis of Study II. Even so, a firm 
causal relationship between nutritional factors and cognitive decline and dementia can 
only be drawn from future longitudinal studies with a longer follow-up period.  
 
It also should be pointed out that that low albumin, low hemoblobin, and low body mass 
index also could be markers of chronic systemic inflammation. Unfortunately, 
inflammation markers (Interleukin 1, Interleukin 6, tumour necrosis factor alpha, C-
reactive protein, etc) were not measure in the present study and we are unable to further 
examine the complex relationships between nutrition, inflammation, and cognition. 
 
Another limitation is that this thesis only covers certain aspects of nutrition, and we are 
still very far from elucidating a full picture of the relationship between nutritional factors 
and cognitive functioning. Therefore, future studies investigating the effect of nutritional 
factors on cognitive function could extensively collect a wide range of nutritional 
assessment data from the same group of elderly people, including dietary intake, 
anthropometric measures, blood concentrations of various macronutrients and 
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 micronutrients, and nutrition physical examination; data systematically collected from the 
same cohort will enable the researchers to examine the synergistic effect of nutritional 
factors on cognitive function as well as the independent effect of each nutritional factors. 
 
To confirm the cognitive benefit of nutritional intervention and nutritional supplements, 
randomized controlled trials targeting at risk population (for example, those with low 
folate and high homocysteine) could be conducted. If firmly established, the correction of 
poor nutritional status and optimization of certain micronutrients blood concentration 
could become part of future dementia prevention practice. Hopefully, we could also 
enhance the cognitive function of healthy older adults through nutritional supplements.  
 
Although an enormous amount of information has been accumulated in recent years of 
research, there is still long way to go before we could successfully prevent dementia and 
optimize cognitive health of the elderly people. I trust the work presented in this thesis 
could add a little more to our growing knowledge of dementia and cognitive function of 
the elderly. Hopefully, the growing epidemic of dementia disease in the 21st century 
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